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ABSTRACT 
Prostate cancer (PC) is generally an androgen-driven disease, why androgen 
deprivation therapy (ADT) is the cornerstone for treatment of advanced and 
metastatic hormone-naïve PC (HNPC). ADT generally offers a good initial response, 
but normally fails with time, and the disease relapses into lethal castration-resistant 
PC (CRPC). Neuroendocrine differentiation (NED) is a transdifferentiation process 
that results in the accumulation of neuroendocrine (NE)-like tumor cells. NED is 
increased in CRPC and in response to ADT, and may represent a therapy-driven 
escape mechanism. Midkine (MDK) is a pleiotropic growth factor that is highly 
expressed during human embryogenesis, but is also induced in many pathological 
conditions, as in most human carcinomas, including PC. In recent years, MDK has 
received increased attention as a tumor biomarker in different human carcinomas.  
In addition to a lack of curative treatments for advanced PC, there is a lack of reliable 
prognostic and predictive biomarkers. There is a need to find new biomarkers and to 
better understand the mechanisms behind castration-induced transformation into 
CRPC, including NED and acquired resistance.  
The purpose of this thesis was to evaluate the role and impact of MDK in PC, with a 
focus on the CR stage and castration induced transformations, including NED. In this 
work we found MDK to be highly expressed both in advanced HNPC and in 
progressed CRPC and that MDK is associated with NED in CRPC. MDK was found 
to be influenced by castration and is presumed to be functionally associated with the 
androgen receptor. MDK was associated with a profound biological role in androgen-
sensitive PC cells in vitro and was found to promote PC cell survival during the 
initial phase of steroid deprivation. Lastly, MDK was demonstrated to represent a 
powerful prognostic biomarker in both advanced HNPC and at relapse into CRPC. 
NED, in response to steroid deprivation, was observed as a transient phase of 
adaptation before transition into castration resistance, and was furthermore inducible 
also in the CR-state in response to AR-targeting.  
In conclusion, this thesis identifies MDK as an important tumor biomarker in PC, 
with the potential to improve clinical decisions in treatment of patients with both 
advanced HNPC and CRPC. Furthermore, the functional importance of MDK in 
tumor evolution was partly elucidated. 
 
Keywords: Castration resistant prostate cancer, neuroendocrine differentiation, Midkine, 
steroid deprivation 
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POPULÄRVETENSKAPLIG 
SAMMANFATTNING 
 
Prostata cancer (PC) är den vanligaste cancerformen hos män i Sverige, med 
årligen ca 10 000 nyupptäckta fall. PC är även en den cancerform som 
orsakar flest cancerrelaterade dödsfall hos svenska män, ca 2350 varje år. PC 
växer ofta långsamt och är begränsad till prostatan och är utan symptom. men 
kan i vissa fall utveckla ett aggressivt tillväxtmönster där tumörceller sprider 
sig utanför prostatan och vidare till andra vävnader och organ som 
dottertumörer, metastaser. 
Patienter med metastaserad PC kan inte botas, utan får i dagsläget bromsande 
och symptomlindrande behandling i form av kastration, oftast medicinsk så 
kallad androgen deprivationsterapi (ADT). Denna behandling blockerar 
produktionen av manligt könshormon, testosteron, från testiklarna, och 
därmed tumörtillväxten eftersom cancerceller i prostata är beroende av detta 
hormon. ADT ger ofta god effekt hos de allra flesta patienter, men tyvärr bara 
en kortare tid eftersom tumörerna normalt återupptar sin tillväxt efter några 
år, då som aggressiv så kallad kastrationsresistent PC (CRPC), för vilken det 
idag finns flera behandlingsalternativ som kan förlänga livet för vissa 
patienter upp till några år.  
Övergången till CRPC förknippas ofta med en återupptagen aktivering av 
testosteron, trots att kastrationsbehandlingen pågår. Detta beror på att cellerna 
ökar sin känslighet för hormonet, eller att de börjat producera testosteron 
själva och därför inte längre är beroende av den normala produktionen. Det 
finns dock en grupp av CRPC patienter vars tumörtillväxt styrs av helt andra 
signaler. Dessa tumörer har ofta en ackumulering av cancerceller som har 
likheter med neuroendokrina celler, inklusive en produktion och utsöndring 
av diverse neuronala proteiner vilka stimulerar tillväxt och överlevnad, så 
kallade neuroendokrin (NE)-lika tumörceller. 
Midkine (MDK) är ett protein som under fosterutvecklingen bidrar till 
bildningen av nervssystemet. Hos vuxna människor finns proteinet i princip 
endast vid sjukdomstillstånd som vid inflammation och olika 
tumörsjukdomar. MDK har i olika cancerformer förknippats med både 
tillväxt och ökad överlevnadsförmåga hos cancerceller, men hur detta sker 
och vad det har för betydelse i PC är delvis oklart. 
För att kunna utveckla effektiva behandlingar mot CRPC, även mot de 
former som har NE-lika tumörceller, behöver vi bättre förstå hur ADT driver 
övergången till CRPC och hur detta leder till förekomst av NE-lika 
tumörceller. Vi behöver även bättre sätt att upptäcka och karaktärisera de 
farliga formerna av PC, och även förbättra metoder att utvärdera effekten av 
olika behandlingar. 
  
Det övergripande målet med denna avhandling har varit att förstå funktionen 
och betydelse av MDK i PC, både före ADT, under utveckling av CRPC, och 
i CRPC, särskilt i samband med en ackumulering av NE-lika tumörceller. 
Dessutom studerades hur PC-celler förändrades av att inte ha tillgång till 
testosteron, och hur de över tid utvecklades till CRPC celler. 
I dessa studier fann vi mycket MDK i vävnad från metastaserad CRPC 
jämfört med vävnad från tidigare, snällare, former av PC. I CRPC fanns 
MDK ofta i områden med mycket NE-lika tumörceller. Detta kunde också 
ses i cellodlingsförsök, där PC cellerna bildade mycket MDK då de 
utvecklades till NE-lika tumörceller efter att ha berövats testosteron. Genom 
att blockera cellernas produktion av MDK kunde vi även påvisa att MDK är 
viktigt för många grundläggande funktioner i en PC cell, så som tillväxt och 
reparation av skadade gener. Vi kunde också se att testosteron påverkade 
bildningen av MDK. 
Dessa resultat tyder på att MDK har en viktig roll för PC. Därför undersöktes 
om analys av mängden av MDK i blodet från patienter med PC kan säga 
något om hur allvarlig PC man har. Studien visar att patienter med höga 
nivåer av MDK redan innan ADT påbörjas resulterar i en kortare livslängd. 
Dessutom visar resultaten att stora mängder av MDK i blodet när CRPC 
utvecklats tyder på att man har kortare tid kvar att leva. 
Genom studier i cellodlingssystem kunde vi även se att utvecklingen av NE-
lika tumörceller är ett övergående steg i processen att utveckla CRPC. Detta 
sker troligtvis som en anpassning till ADT och leder till utveckling av 
egenskaper hos PC cellerna för att överleva trots låga nivåer av manligt 
könshormon.  
 
Sammanfattningsvis visar denna avhandling att MDK är viktig i metastaserad 
PC särskilt i relation till utveckling av CRPC och associerad ackumulering av 
NE-lika tumörceller, och att analys av MDK skulle kunna förbättra 
kunskapen om patienters PC sjukdom och prognos. 
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1 INTRODUCTION 
1.1 CANCER 
Cancer is one of the leading causes of death worldwide and represents a collection of 
genetic diseases, all defined by uncontrolled cell proliferation. The array of human 
cancers is made up of around 200 different diseases, each generated from different 
cell types in the human body (1). 
 
Most cancers, approximately 90% in humans, have an epithelial origin (endo- or 
ectodermally derived) and are known as carcinomas. A subtype of carcinoma, 
adenocarcinoma, arises from epithelial cells of glandular origin, for example, breast 
and prostate glandular tissue. The remaining non-epithelial cancers are mainly 
represented by neuroectodermal tumors and sarcomas. Neuroectodermal tumors are 
derived from cells in the central and peripheral nervous system, while sarcomas are 
of mesenchymal origin (e.g. cartilage, bone, or fibrous tissue). Furthermore, cancers 
of the blood, leukemia and lymphomas, represent subclasses of sarcoma that are of 
hematopoietic origin, arising from blood-forming cells and from cells of the immune 
system, respectively While most cancers grow as solid masses of cells, i.e. tumors, 
cancer of the blood grow as individual cells (2, 3). 
 
Primary cancer is a tumor mass present at the site of initial transformation and is 
normally of little clinical obstacle, excised by surgery or cured by localized treatment 
Secondary cancer, i.e. metastasized cancer, represents a colonization and regrowth of 
primary tumor cells at distant sites and in contrast to primary cancer, metastasized 
cancer represents a great clinical challenge and accounts for the vast majority of 
cancer related deaths (4, 5). 
 The initiation and progression of cancer  1.1.1
Tumorigenesis refers to the process of tumor formation, including both benign 
(indolent) and malignant (invasive, aggressive) tumors, while carcinogenesis refers 
to the formation of malignant tumors, i.e. the development of cancer. Malignant 
tumors are characterized by their ability to invade nearby tissue and to spread to 
distant secondary sites via the circulatory or lymphatic systems through the process 
of metastasis (2, 3). 
 
The initiation of cancer is a multistep process whereby normal cells are gradually 
transformed into cancer cells through a sequential accumulation of epigenetic 
alterations and mutations within the genetic material of the cell, the DNA. These 
acquired genetic changes eventually lead to uncontrolled clonal growth. Cancer cells 
tend to adhere poorly to each other, and invasive cancer cells possess the ability to 
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transform into a migratory phenotype through the process of epithelial to 
mesenchymal transition (EMT). During EMT, many cancer cells also upregulate the 
expression of different secretory proteases that will assist in the digestion of 
surrounding tissues. Without growth regulation, continuous cell expansion eventually 
leads to cell dissociation, EMT, and migration, and tumor cells that finally leave the 
primary tumor site through invasion and metastasis. The progression of cancer is 
characterized by continuous clonal selection of tumor cells with progressively 
increasing capacity for proliferation, survival, invasion, and metastasis (2, 3).  
 
Similar to tumor initiation, metastasis is a multistep process. The initial steps 
preceding metastasis, i.e. the growth of the primary tumor, require the initiation of 
angiogenesis. The metastatic process then begins with tumor cell intravasation into 
the circulatory system (in blood vessels or lymphatics). Of the circulating tumor cells 
it is estimated that less than 0,1% (6) will survive the hostile environment, and many 
of the surviving cancer cells will exist in an arrested state in the circulation for longer 
periods before extravasation. At extravasation, the tumor cells leave the circulation 
and invade their new organs or tissues (2, 3). Common sites for metastatic spread 
include lymph nodes, lungs, the liver and the skeleton (National cancer institute; 
https://www.cancer.gov/types/metastatic-cancer). In this new environment, many 
disseminated tumor cells die or become dormant, sometimes for many years. 
Eventually, individual tumor cells might give rise to micrometastases through 
initiated proliferation. If the proper conditions are met, continuous growth will 
thereafter result in clinical metastases for which the initiation of angiogenesis is 
required. With induced angiogenesis, seeding of new metastases is further enabled 
(2, 3) 
 Hallmarks of cancer 1.1.2
Genetic susceptibility to cancer is determined by genetic variations that are inherited 
as well as by variations and alternations that are acquired during life. Cancer is 
therefore a disease associated with aging due to the time-dependent accumulation of 
genetic mutations, epigenetic alterations and cellular damage, and many key features 
of cancer cells and aging cells are thus shared, for example, genomic instability and 
epigenetic modifications. Cancer and aging differ however in that cancer cells have a 
‘gain of function and fitness’ whereas aging cells are characterized by a ‘loss of 
function and fitness (7). 
 
Genome instability and mutations are considered to be enabling characteristics of 
cancer, as described by Hanahan and Weinberg (8). Loss of function mutations in 
tumor suppressors and gain of function mutations in growth promoting proto-
oncogenes are essential for the development of cancer. Also, mutations and 
modifications leading to loss of functions of genes involved in the DNA damage 
response are of central importance for cancer initiation and progression (3, 8, 9).  
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In addition to genomic instability and mutations, tumor-promoting inflammation is 
also considered an enabling characteristic, which highlights the close relationship 
between inflammation and cancer (10-13). The original six hallmarks as described by 
Hanahan and Weinberg in (9) are activation of invasion/metastasis, induction of 
angiogenesis, apoptotic escape, replicative immortality, sustained proliferation, and 
the ability to evade growth suppressors. In addition, two emerging hallmarks have 
been added to the six original features of cancer – the deregulation of cellular 
energetics and the ability to avoid immune destruction (8). 
1.2 THE PROSTATE GLAND 
 Anatomy and physiology 1.2.1
The prostate, a walnut-shaped exocrine gland, is located in the pelvis below the 
urinary bladder (14) and is of endodermal origin. It arises from the proximal part of 
the urethra through epithelial budding into the surrounding mesenchyme. Under the 
influence of androgens and EMT interactions, epithelial budding is followed by 
glandular differentiation and branching morphogenesis to generate an epithelial-lined 
glandular and ductal system, while the mesenchyme differentiates into a dense 
fibromuscular stroma. Prostate organogenesis and maturation continue until the gland 
reaches its full size during puberty (15). 
 
The human prostate, which is enclosed by a capsule-like structure, can be divided 
into three glandular zones – the peripheral zone, the transitional zone and the central 
zone, as well as one non-glandular zone termed the anterior fibromuscular stroma. 
The transition zone represents the exclusive site of benign prostatic hyperplasia 
(BPH) initiation, a common nonmalignant condition found in older men. The 
peripheral zone is the largest zone, containing the majority of the glandular tissue 
(about 70%), and representing the most common origin of prostate cancer (PC) and 
premalignant lesions such as prostatic intraepithelial neoplasia (PIN) (14, 16). 
 
The prostate is part of the male reproductive system and produces a weakly alkaline 
secretion that drains into the urethra together with spermatozoa and secretions from 
the seminal vesicles at ejaculation (17). The prostatic secretion, which contains 
numerous proteins, ions, and electrolytes, functions as a liquefying agent that 
enhances sperm motility and survival, hence aiding in fertilization. The alkaline 
property of the secretion furthermore protects the sperm from the acidic environment 
of the vagina (18, 19). As a liquefying agent, one of the main functions of the 
prostatic secretion is proteolysis, and prostatic secretions are therefore rich in 
proteolytic enzymes of which one of the major constituents is the serine protease 
prostate specific antigen (PSA), also known as kallikrein III (KLK3). 
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 Morphology and cell function 1.2.2
The glandular structures of the prostate are composed of an epithelial bilayer 
containing three distinct types of cells – secretory luminal cells, basal cells and a 
minor population of neuroendocrine (NE) cells. In addition, a small fraction of stem 
cells with basal cell characteristics is also believed to be scattered within the 
epithelium. An underlying basement membrane separates the epithelium from the 
surrounding stroma (Figure 1) (20, 21).  
Prostatic epithelial cells are identified by their morphology, location, and distinct 
patterns of marker expression. 
 
 
Figure 1. Schematic illustration of the human prostate epithelial compartment, the lining 
glandular ducts and acini, and the underlying stromal compartment. Adapted from (15) with 
permission. 
 
The inner epithelial layer, facing the lumen of the duct, is made up of polarized 
columnar-shaped luminal cells (Figure 1), and these represent the predominant 
prostatic epithelial cell type. They produce and secrete the components of the 
prostatic fluid, including PSA, directly into the prostatic lumen. They are terminally 
differentiated and post-mitotic, have a high androgen receptor (AR) expression and 
are androgen dependent. They are further characterized by the expression of luminal 
cytokeratin (CK) 8 and CK18 (20, 21).  
 
The outer epithelial layer, resting on the basal membrane, is made up of cuboidal 
basal cells, which represent the second major population of prostatic epithelial cells 
(Figure 1). The function of the basal cells is not fully understood, but in contrast to 
luminal cells, they lack a secretory function and are relatively undifferentiated, 
express low or undetectable levels of AR, have no PSA expression, and are 
independent on androgens for survival and growth. They are further characterized by 
the expression of P63 and basal CK5 and CK14. A fraction of the basal cells 
scattered within the basal cell layer are believed to represent a prostatic stem cell 
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population, and as such these cells are able to differentiate into the other epithelial 
cell types if needed. This is believed to occur via a basal-luminal intermediate (transit 
amplifying) cell type that expresses both basal and luminal CK, CK5 and CK18, as 
well as additional markers such as CK19. This undifferentiated population is AR 
negative, hence androgen independent (15, 22) and have been demonstrated to 
possess tumor initiating capabilities (23). 
 
The third cell type, the NE cells, are scattered within the basal cell layer, and like the 
luminal cells, are terminally differentiated and post-mitotic (Figure 1). The NE cells 
are however AR negative and androgen independent. Furthermore, they produce 
numerous secretory products, including many neuropeptides, and are believed to 
support and regulate the growth, survival, and differentiation of surrounding 
epithelial cells in a mainly paracrine fashion (21). They can be of opened or closed 
morphology, where the opened NE cells extend dendritic protrusions toward the 
lumen. The NE cells are mainly characterized by the expression of different NE 
markers for example chromogranin A (CHGA) and neurons specific enolase (NSE) 
(24). They are furthermore characterized by express of a mixed basal – luminal CK 
pattern of CK5 and CK8 (22).  
 
The prostatic stroma is composed of a heterogeneous mixture of cells, including 
mesoderm-derived smooth muscle cells and fibroblasts as well as infiltrating immune 
cells. The cells are embedded in a collagenous matrix together with blood vessels, 
lymphatics, and nerves (15). Both the stromal smooth muscle cells and the fibroblasts 
are to AR positive and produce andromedins – which are growth and survival-
promoting peptides – in response androgen/AR signaling. The andromedins diffuse 
into the epithelial compartment where they control the growth and survival of both 
the luminal and basal cells (15, 25, 26). 
 Androgen biosynthesis and AR activation 1.2.3
Androgens belong to a group of steroid hormones that promote the development and 
maintenance of the male sex characteristics. The prostate gland, as part of the male 
reproductive system, is highly dependent on androgens for normal development, 
growth, survival and function (15). The cellular response to androgens is mediated by 
the AR, which regulates a complex genetic program, affecting fundamental processes 
such as proliferation and differentiation as well as the DNA damage response (27, 
28) 
 Androgen biosynthesis 1.2.3.1
Circulating androgens are produced, in the testes and in the adrenal glands, under the 
regulation by the hypothalamic–pituitary axis (Figure 2). Endocrine secretion of the 
hypothalamic hormones, gonadotropin releasing hormone (GnRH) and corticotropin 
releasing hormone (CRH) regulate the secretion of the pituitary gland hormones 
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luteinizing hormone (LH) and adrenocorticotropic hormone (ACTH), respectively. 
Testicular androgen in the form of testosterone is produced by the Leydig cells of the 
testes in response to LH, while the production of adrenal androgens, mainly made up 
of the weak androgen precursors dehydroepiandrosterone sulphate (DHEA-S, 
predominantly), DHEA, and androstenedione (AD), is regulated by ACTH (Figure 
3A). Testicular androgen in the form of testosterone accounts for 95 % of the 
circulating androgens while the adrenal androgens account for the remaining 5% 
(29).  
 
Figure 2. Androgen synthesis and regulation of the prostate gland. The illustration is reused 
from (30), with permission.  
 Androgen receptor activation  1.2.3.2
Testosterone as well as adrenal androgens enter the stromal and epithelial cells of the 
prostate by passive diffusion. Within the prostatic cells, testosterone is converted into 
dihydrotestosterone (DHT) by one of two isoenzymes, steroid 5α reductase 1 
(SRD5A1) or SRD5A2, of which SRD5A2 predominates within the normal prostate. 
Both testosterone and DHT can bind and activate the AR, but DHT has a higher 
binding affinity and is a more potent androgen. Also the adrenal androgens can be 
converted into testosterone or DHT within peripheral tissues, including the prostate, 
for which the central enzymes include, 3β-hydroxysteroid dehydrogenase/Δ5-4- 
isomerase type 1 (3β-HSD), 17β-hydroxysteroid dehydrogenases (17β-HSD), aldo-
keto reductase family 1 member (AKR1C3), and SRD5A (Figure 3B) (31).  
 
In the prostate, the AR is present in both the stromal compartment (fibroblasts and 
smooth muscle cells) and in the secretory luminal cells of the epithelial compartment, 
while the basal cells and the NE cells are AR negative. Inactivated, ligand-free AR is 
present in the cytosol of AR-positive cells, where it is bound by heat shock proteins 
(Hsp-70 and Hsp-90) that stabilize the receptor and protect it from degradation. 
Androgen binding to the AR induces a conformational change that results in the 
dissociation of bound heat shock proteins (29). The ligand-receptor complex 
becomes stabilized and activated through subsequent homodimerization and 
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phosphorylation. The activated complex is thereafter translocated to the nucleus 
where, together with RNA polymerase II and diverse co-factors (co-activators or co-
repressors), it binds to DNA target sequences known as androgen response elements 
(AREs) in order to activate or repress gene expression (Figure 3B) (31). 
	
  
 
Figure 3. A. Androgen biosynthesis in the adrenal gland results in three main androgen 
precursors; DHEA-S (the predominant precursor), DHEA, and AD. De novo steroidogenesis 
from cholesterol also occurs in the Leydig cells of the testes, where the biosynthesis proceeds 
all the way to the potent androgen, testosterone. B. Conversion of testosterone and adrenal 
androgens into the potent androgen, DHT occurs within prostatic stromal and epithelial cells. 
AD conversion into DHT occurs through two alternative pathways (i versus ii), where the 5α-
dione pathway (i) represents a DHT bypass pathway that predominates in CRPC, while the 
testosterone pathway (ii) represents the normal route. Abbreviations: T, testosterone; CRPC; 
castration resistant PC, RNA pol II, RNA polymerase II; CoA, cofactors. The illustration is 
redrawn, inspired of PA Watson et al (31). Regarding abiraterone acetate (androgen 
biosynthesis targeting drug) and enzalutamide (AR-targeting drug), see section 2.3.2; Prostate 
Carcinogenesis. 
1.3 PROSTATE CANCER 
 General background 1.3.1
In the industrialized Western world, PC is the most commonly diagnosed cancer in 
men and is the third leading cause of cancer-related deaths (32), this despite many 
therapeutic advances in recent year. In Swedish men, PC represents both the most 
commonly diagnosed cancer form and the most common cancer-related cause of 
death, with approximately 10,000 new cases diagnosed and 2.350 reported deaths 
annually in recent years (Cancer statistics in Sweden; 
http://www.socialstyrelsen.se/statistik/statistikdatabas/cancer). 
 
Over the past decades, the incidence of PC has increased dramatically in most 
countries, especially in the Western world, while the PC mortality rate has remained 
fairly constant. The steady increase in PC incidence is primarily due to widespread 
PSA testing, which was introduced as a clinical option in the late 1980s (33) but is 
A.  B. 
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also likely influenced by an aging population, due to the close association between 
PC and increased age (34). 
In recent years, however, an ongoing decrease in mortality rate can be observed in 
many countries, for example in Sweden, the US and the UK (35). The decrease in PC 
mortality is likely due to recent advances in PC treatment options as well as to the 
earlier detection of PC due to PSA testing. The majority of the PC cases detected are 
thus represented by organ-confined primary tumors that are potentially curable 
through radiation or surgery, and to a less extent by lethal metastatic disease (36, 37). 
 
A substantial portion of the primary tumors detected are however low-risk PC, i.e. 
tumors that will never progress or will only very slowly progress from a localized 
tumor to a locally advanced or a metastatic stage (37). Today there is no reliable 
diagnostic tool to differentiate between indolent and aggressive forms of PC and to 
predict clinical progression, and this remains one of the major challenges within the 
PC field (37, 38). To prevent overtreatment of indolent tumors, active surveillance is 
today the first choice for this patient group (39) (http://www.socialstyrelsen.se). 
 
In addition to cancer, the prostate is subject to pathologies of prostatitis 
(inflammation) and BPH, both of which are more common in elderly men, as well as 
associated with increased PSA levels (40, 41). BPH presents as an enlargement of the 
prostate, including both the stromal and the epithelial compartments, and can, when 
sufficiently enlarged result in compression of the urethral canal and further 
complications (41). Prostatitis refers sometimes to a histological inflammation, 
sometimes chronic, that might be associated with an increased risk for PC (11). 
 Risk factors  1.3.1.1
PC incidence, like the incidence of many other cancer forms, is strongly related to 
age, with clinical PC only being frequent in men over 60–65 years (42). The strong 
association between PC and age is at least partly due to the accumulation of genetic 
and epigenetic alterations that occur over time. Examples of genes that are 
commonly modified during the course of PC progression are the tumor suppressors 
NKX3.1, CDKN1B, TP53 and PTEN and the oncogenes AR, MYC and ERG (11).  
In addition, as is also true for cancer in general, genetic inheritance can influence the 
predisposition for PC initiation and progression, and several susceptible genes have 
been identified, including BRAC2, RNASEL, MSR1 and CHEK2, however all with 
low frequencies of genetic variation in the risk population (34). Although several of 
these genetic alterations represent strong risk factor within families (43), most PC 
cases appear to be sporadic with less than 10% estimated to be accounted for by 
heritable forms (40). PC incidence is much higher in men of Afro-american 
compared to other populations. 
In addition, environmental factors, diet, and lifestyle are considered emerging risk 
factors for PC, as indicated by higher PC incidences in Europe and the US compared 
to in Asia. In support of an association between environmental and lifestyle factors 
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and PC, the risk of developing PC increases markedly in native Asians who migrate 
to the US (11, 34). As mentioned above, inflammation of the prostate , including 
lesions such as proliferative inflammatory atrophy (PIA) is considered to be 
associated with the development of PC (10-12). 
 Diagnosis and pathology 1.3.1.2
PC is diagnosed as localized, locally advanced, or metastatic disease. Localized PC 
refers to invasive growth within the prostate gland, while locally advanced PC is 
characterized by invasive growth and spread outside the prostate capsule. Metastatic 
disease refers to the spread of tumor cells to distant sites through the lymphatic 
system or the circulation (34, 40). The most common site for PC metastasis is in 
lymph nodes (44) and in bone, with estimates of about 90% of men with metastatic 
castration-resistant (CR) PC (CRPC) developing bone metastases. Furthermore, as 
estimated from autopsy studies, bone metastases are found in around 70% of men 
who die from their PC (45, 46), and thus appear to be responsible for the vast 
majority of the morbidity and mortality in PC (20, 45).  
 
Early-stage PC is often asymptomatic while locally advanced or metastatic disease is 
more often associated with severe symptoms like hematuria, lower urinary tract 
symptoms, bone pain, and fractures. Early-stage PC is thus commonly detected by a 
routine PSA blood test that is followed by further examination due to the low 
specificity and sensitivity of PSA. Examinations that follow an elevated PSA 
measurement include multiparametric magnetic resonance imaging (MRI) and 
transrectal ultrasound-directed biopsy sampling, where the ultrasound gives 
information about the size and the shape of the prostate and the MRI mght detect 
areas in the prostate suspicious for cancer (34, 40, 47).  
The collected biopsies are histologically examined by a pathologist for assessment 
concerning differentiation (Gleason Score (GS)) as a measurement of aggressiveness. 
After PC has been confirmed, additional examinations might be performed, for 
example, if metastatic spread is suspected as is the case in patients with a high PSA 
level in combination with a high GS. Examinations to determine metastatic spread 
include bone scintigraphy, MRI, computerized tomography (CT), and positron 
emission tomography-CT (PET-CT). The combined information is used for 
classification into different risk categories (34, 40, 47). 
 PSA and other biomarkers for PC 1.3.1.3
Normal prostate architecture prevents PSA from reaching the circulation; however, 
during prostate pathologies, including BPH, prostatitis and PC, the epithelial layer 
and the underlying basement membrane become leaky, this in combination with an 
increased production of PSA, resulting in increased PSA levels that are detectable in 
the blood (48, 49). An increased PSA blood level might thus indicate PC, but is not 
sufficient for cancer diagnosis. Furthermore PSA cannot differentiate between 
indolent and aggressive forms of PC (38). A PSA level of 0–3 ng/mL is considered 
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normal, a level above 10ng/mL is considered indicative of local tumor growth, and a 
PSA value above 100ng/mL is considered indicative of metastatic disease. However, 
the majority of men with a PSA value of 3–10 ng/mL does not have PC but the 
benign condition BPH (40). In addition to the high proportion of false positives, PSA 
measurement is also associated with false negative results, i.e. patients with 
aggressive PC but without an elevation in PSA (38). 
 
In addition to PSA, other biomarkers are sometimes evaluated at diagnosis, for 
example, alkaline phosphatase (ALP). ALP is primarily used to evaluate the degree 
of bone remodeling and hence the degree of metastatic burden (34, 40, 50). 
Furthermore, NE marker(s), for example chromogranin A (CHGA), neuron specific 
enolase (NSE), CD56 (also known as NCAM1), and/or synaptophysin (SYP) can be 
used when an evaluation of the degree of neuroendocrine differentiation (NED) is of 
interest (24, 51). An accurate estimate of the amount of NE-like tumor cells can, 
however, be difficult to achieve due to the heterogeneous nature of NE-like tumor 
cells and the lack of a consistent marker (47, 52, 53).  
 Gleason score 1.3.1.4
The GS is a histological grading system to assign PC aggressiveness according to the 
degree of differentiation. First, the growth patterns of the tumor is assigned with 
Gleason grades, 1 to 5, with 1 being the least aggressive and 5 the most aggressive 
(the most dedifferentiated) (54). The GS is the sum of the most common and the 
most aggressive Gleason grades found in the tumor.  
According to the new WHO guideline from 2016 (55), Gleason grade 3 should be the 
lowest grade to assign PC, and therefore a modified grading system now range from 
GS 6 to 10. The GSs are further divided into different grade groups, 1 to 5, with 5 
being of highest risk for progression. The GS is generally considered a good 
prognostic factor (56, 57) where patients with GS 6 are classified as having a low 
risk for progression (grade 1), while patients with GS 8 (grade 4) and GS 9-10 (grade 
5) are classified as high risk. GS 7, the most common score at diagnosis, has however 
a history of low prognostic value and should according to the new guideline from 
2016 be separated into two different risk groups according to the Gleason pattern; 
gleason 3+4 (grade 2) versus 4+3 (grade 3), with significantly worse prognosis for 
the latter (55). 
 TNM staging 1.3.1.5
The TNM staging system is a clinical classification that takes into account the tumor 
(T) and the presence of regional lymph node metastases (N) and distant metastases 
(M). Tumor stages T1 (non- palpable) and T2 (palpable) comprise tumors that are 
still confined within the prostate, while T3 and T4 stages comprise tumors that have 
penetrated the prostate capsule and spread into the surrounding tissue. In all T-stages, 
there is a possibility of metastatic spread, but the risk is increased in T3 and T4 
stages. In addition, the tumor stages TX and T0 refer, respectively, to a primary 
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tumor that cannot be assessed and to no evidence of primary tumor. The M stages, 
MX, M0, and M1 refer, respectively, to distant metastases not assessed, not present, 
and present, while the N stages NX, N0, and N1 refer, respectively, to regional 
lymph node metastases not being assessed, not present, and present (National Cancer 
Institute; https://www.cancer.gov/about-cancer/diagnosis-staging/staging). For M1 
patients the prognosis is poor, with an average survival of 24–48 months, while the 
prognosis for N1 patients is much better with a median cancer-specific survival 
(CSS) of 8 years (34). 
 Prognostic risk groups PC stages 1.3.1.6
Prognostic risk groups for patients with localized PC, refers to the estimated risk – 
low, intermediate or high for progression into invasive growth and metastatic disease 
– and are based on the pre-treatment evaluation of T-stage, GS and PSA level (34). 
The overall PC stage, I to IV, refers to the progression state of the disease, with stage 
IV being the most aggressive stage represented by advanced disease (N1 and/or M1) 
– based on the PSA level, TNM staging and GS at diagnosis. Stage 4 is further 
divided in N1 versus M1 disease (American Cancer Society; 
https://www.cancer.org/cancer/prostate-cancer/detection-diagnosis-
staging/staging.html). 
 Prostate carcinogenesis 1.3.2
 Androgen dependence 1.3.2.1
PC originates in the prostatic epithelium and is generally believed to arise from 
transformed luminal cells due to the androgen dependence of most PC tumors as well 
as to the expression of luminal markers in PC cells. The PC origin is, however, still a 
matter of some debate, with theories of a basal cell origin as well as a cancer stem 
cell or intermediate cell origin. Because PC stem cells do not express AR and 
therefore are truly androgen independent (20, 58, 59), their implication in PC 
initiation and/or progression is of central importance, especially concerning the 
transformation to a castration-resistant (CR) disease.  
 
The normal prostate – as well as PC initiation and progression – is androgen 
dependent for growth, survival, and function (60). In the normal prostate, growth and 
maintenance of the prostate epithelium depends on paracrine signaling of 
andromedins (including growth factors and survival factors) produced by supporting 
stromal cells (smooth muscle and fibroblasts) in response to AR signaling (25). 
Androgen-induced AR signaling within the luminal cells is however required for the 
production of secretory proteins such as PSA and human kallikrein-2 and is 
furthermore growth suppressive, resulting in G0 growth arrest and terminal 
differentiation into secretory cells (26). During transformation into PC, the paracrine 
regulatory function mediated by stromal AR is lost and replaced by AR autocrine 
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regulation in the epithelial tumor cells. Furthermore, in these epithelial tumor cells, 
AR signaling goes from being growth suppressive to growth stimulatory (25, 26), 
usually measurable as an elevated level of PSA in the circulation due to a leaky 
epithelial compartment (REF). The transformed epithelial cells, now producing their 
own growth and survival factors become less dependent on the stromal cells. The 
oncogenic transformation of the AR, going from growth suppressive to growth 
promoting, is associated with an AR–regulated increase in MYC expression, an 
oncogene commonly upregulated in different human carcinomas (61). 
 PC initiation and progression  1.3.2.2
PC is a multifocal and heterogeneous disease and is therefore believed to arise from 
multiple neoplastic foci that emerge and evolve independently, while metastases are 
believed to be clonally related and derived through selective advantages of individual 
clones (20). The progression of PC as well as cancer progression in general is a 
multistep process, that in PC involves – PIN, localized PC, locally advanced PC, 
metastatic disease and CR advanced and/or metastatic disease (Figure 4). 
 
PIN and PIA 
In PC, malignant tumors are believed to proceed from premalignant lesions known as 
PIN. PIN is characterized by luminal epithelial hyperplasia (increased proliferation) 
in combination with a reduction of basal cells, but with an intact basal membrane, 
resulting in intraglandular cell growth (Figure.4).  
The premalignant cells of PIN are further characterized by cell depolarization and 
nuclear atypia and enlargement (20). (PIA) is a state of epithelial atrophy in 
combination with increased proliferation. Commonly, there is also increased stromal 
infiltration of inflammatory cells (11). PIA is a proposed precursor state of PIN as 
well as of PC (10, 11). The incidence and extent of both PIN (62) and PIA (11) are 
increased with age. 
 
Localized and locally advanced PC 
The progression of PIN to malignant lesions is characterized by the loss of the basal 
cells, disruption of the underlying basal membrane, and further invasion of tumor 
cells into the surrounding stromal compartment (Figure 4) (20). The primary tumor 
development goes from localized to locally advanced PC. Localized PC is confined 
within the prostate gland, while locally advanced PC is characterized by the 
penetration of the prostatic capsule and invasion of surrounding tissues, but without 
lymph node involvement or distant metastases (Cancer Research UK; 
http://www.cancerresearchuk.org/about-cancer/prostate-cancer).  
 
Metastasis 
Metastasis refers to the spread of tumor cells to distant locations, colonization, and 
regrowth (Figure 4). Metastatic PC almost invariably metastasizes to bone, and 
furthermore presents as characteristic osteoblastic rather than osteolytic lesions (20, 
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45) In addition to bone, PC also commonly forms metastases in the lymph nodes as 
well as in the lung and liver (63, 64). Extensive bone metastases are primarily 
responsible for PC patient morbidity and mortality (20, 45).  
 
 
Figure 4. The progression of PC is a multistep process, and a potential curative treatment is 
only available before the transition to CR growth and/or metastatic disease. A. PC 
progression: Tumor cell transformation is normally initiated in premalignant lesions i.e. PIN. 
PIN lesions potentially can progress into prostate carcinoma, from localized to locally 
advanced and further to metastatic disease. Disease recurrence after primary castration 
treatment is referred to as CRPC, and normally occur as a metastatic disease but, however, 
sometimes within the prostate. B. Treatment: Localized PC is followed by active surveillance 
or is treated with curative treatment depending on the estimated progression risk. Locally 
advanced PC is treated with curative treatment under some conditions, but normally with 
castration (surgically or, more commonly, chemically) in combination with radiation. For 
CRPC, there is currently no curative treatment, but only palliative options.  
 
Castration-resistant PC (CRPC) 
Disease recurrence after castration normally occurs after a couple of years, when the 
cancer has transformed into CRPC. Normally, disease recurrence occurs as 
metastatic disease, but it can sometimes occur locally in the prostate (65), in which 
case metastatic spread follows after CRPC transition (Figure 4). Relapse into CRPC 
is identified by a rising PSA level or from radiological and/or symptomatic 
progression despite ongoing castration therapy(34). 
 Treatment of localized PC 1.3.3
Treatment options for localized PC include active surveillance, radical 
prostatectomy, and radiation therapy. Radical prostatectomy and radiation therapy 
aim to remove the tumor, while active surveillance is carried out through regular 
controls followed by treatment in case of disease progression. Active surveillance is 
the choice for patients assessed with clinically low-risk PC, commonly in 
combination with a short life expectancy, while curative prostatectomy or 
radiotherapy commonly is the choice for patients with longer life expectancy and/or 
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with more poorly differentiated tumors (34). Active surveillance is, however, 
becoming a more common first option due to a history of over treatment of low-risk 
PC tumors (39). 
In Sweden, removal of the prostate gland with radical prostatectomy is the most 
common curative treatment (34). Of patients that have undergone curative treatment 
in the form of prostatectomy or radiotherapy, about 30% will experience cancer 
relapse (66). 
 Treatment of advanced PC  1.3.4
Advanced PC, including high-risk localized PC, locally advanced PC, and metastatic 
and/or CR disease, is characterized by invasive growth. Locally advanced PC has 
already penetrated the prostate capsule and spread to the surrounding extraprostatic 
tissue, while localized PC still grows within the prostate but is assessed as aggressive 
and rapidly progressive. Advanced localized PC should fulfill at least one of the 
following criteria: GS of 8 to 10, ≥T2c, or PSA > 20 ng/ml (34). 
 
Androgen deprivation therapy 
Castration, i.e. removal of circulating testosterone can be achieved by surgical 
castration (removal of the testes) or more commonly through chemical castration i.e. 
androgen deprivation therapy (ADT). ADT represents the cornerstone for primary 
treatment of locally advanced and metastatic HNPC. The beneficial effect of ADT in 
PC treatment was described already by Huggins and coworker in 1941 for which 
they were later awarded the Nobel Prize (67, 68). 
 
During ADT, the production of testicular testosterone is suppressed by the 
administration of GnRH agonists or antagonists that disrupt the hypothalamic-
pituitary-gonadal axis and hence the production of testosterone by the Leydig cells of 
the testes (Figure 2). The effect of androgens can be further blocked by AR 
antagonists, for example, bicalutamide, which are sometimes administrated together 
with ADT in what is known as total androgen blockade (34)The efficiency of ADT is 
referred to as the achieved testosterone level, where a castrated level is defined as < 
0.5 nmol/l in comparison to the normal level of about 10 nmol/l (40).  
ADT initially displays good clinical effect with tumor regression (decreased 
proliferation and increased apoptosis) and symptomatic ease, this in approximately 
80% of the patients (34), although with considerable variation in response durations 
between patients (69). Tumor regression results in an approximately 30% reduction 
in prostate volume after a couple of months of treatment (70), a progression that 
normally can be followed by a decrease in circulating PSA (65), both due to the 
reduced tumor burden but likely also due impaired secretory function in persisting 
cells. Unfortunately, however, ADT fails, normally within a few years, and the 
disease relapses into lethal CRPC (65), this commonly as a metastatic disease. 
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ADT is therefore only palliative, and advanced and metastatic disease considered 
incurable.  
 
Locally advanced and metastatic PC 
For patients with locally advanced PC, local treatments like surgery and radiation 
therapy are less likely to eliminate the cancer by themselves but can sometimes be 
offered in the form of radiation therapy. The first-line option for locally advanced PC 
is, however, normally a combination of radiotherapy and ADT (71), due to the 
androgen dependence of most prostatic tumors.  
Hormonal therapy also represents the first-line option for metastatic disease (34), this 
commonly in combination with other treatments, due to observed survival benefits 
compared to the administration of ADT alone. The combination therapy of the 
cytotoxic drug docetaxel together with ADT is since recently the new recommended 
primary treatment for patients with HNPC with a high metastatic burden. A 
combination therapy of abiraterone acetate (CYP17A1 inhibitor, Figure 3A) and 
ADT is also a promising new primary treatment for patients with metastatic HNPC, 
this regardless of tumor volume (38, 69, 72). Although these combination therapies 
have improved overall survival in recent years, most patients will relapse with time.  
 
Treatment of CRPC 
Recurrent CRPC, commonly metastatic, represents an aggressive and highly 
resistant disease that despite recent therapeutic advances still has an average 
survival of only approximately 3–4 years (69).  
With some exceptions, there is a reactivation of AR signaling during castrate 
conditions, a reactivation that is considered crucial both for CRPC transition and for 
its continued growth (31, 38), due to which hormonal therapy in the form of ADT 
continues to represent the backbone therapy also at this stage of the disease. The 
continued reliance on AR signaling in CRPC has in recent years also been confirmed 
from the survival advantages seen for androgen-targeted and AR-targeted therapies 
using abiraterone acetate and enzalutamide (Figure 3), respectively, both approved 
for chemotherapy-naïve and post-chemotherapy metastatic CRPC treatments (31, 
73). In addition to the novel androgen/AR-targeting therapies abiraterone acetate and 
enzalutamide, several other potent drugs are now available for combination therapy 
with ADT, including – chemotherapy with cabazitaxel and docetaxel and radiation 
therapy with radium-223 (69). These new targeted therapies offer no cure, but 
increase overall survival by a number of moths before relapse and acquired resistance 
(69). 
Furthermore, for treatment of bone metastases, radium-233, zoledronic acid 
(inhibition of osteoclasts) and denosumab (targeting of RANK ligand) could be 
considered, this to prevent and delay cancer-related skeletal events in CRPC (74). 
 
Neuroendocrine PC (NEPC) represents an aggressive subtype of CRPC that has low 
or no dependence on the AR, and it believed to develop as a resistance mechanism to 
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castration and AR-targeted therapies (75), supported by recent observations that 
acquired resistance to abiraterone acetate and enzalutamide is associated with 
increased NED (76, 77). 
 Resistance mechanisms in CRCP  1.3.5
Disease progression leading to CRPC transition as well as the progression of CR 
disease is most commonly AR-driven, at least during the earlier stages, and involves 
the acquisition of different resistance mechanisms related to AR signaling (31, 38). 
There is, however, a subset of CRPC tumors that progress with little or no 
dependence on classical AR signaling, and this is often in association with lineage 
plasticity, the loss of luminal markers, and the acquisition of diverse NE features, 
hence the formation of NE-like tumor cells and further development into NEPC (31, 
78). Dedifferentiated, AR-independent tumors without typical NE features can also 
evolve, commonly referred to as anaplastic PC (75).  
Both AR-dependent and AR-independent resistance mechanisms are believed to 
evolve through adaptation to castration and AR inhibition. Resistance mechanisms to 
ADT and AR-targeted therapies can be divided into three general categories – 
restored AR signaling, AR bypass, and complete AR independence (31). Concerning 
AR signaling in CRPC, it has furthermore been shown that the AR regulates a 
distinct but overlapping transcriptional program compared to in HNCP (28). 
 Restored AR signaling 1.3.5.1
Restored AR signaling can be achieved through several mechanisms, including AR 
amplification, AR-activating mutations, AR splice variants (ARVs), and intratumoral 
steroidogenesis. Restored AR signaling through any or a combination of several of 
these mechanisms is relatively common in CRPC (31). 
 
AR amplification 
AR amplification (Figure 5.1), which results in elevated AR levels, enhances the 
response to the limited androgens, and this is a common mechanism in CRPC and is 
estimated to occur in up to 30% of all patients. AR amplification is, however not 
common in HNPC and the mechanism hence considered to be treatment dependent 
(31). 
 
AR-activating mutations 
AR-activating mutations in PC are mainly represented by four different point 
mutations (L702H, W742C, H875Y, and T878A), all located in the ligand binding 
domain of the AR. These mutations share the property of promiscuous AR activation 
by non-canonical steroid ligands such as adrenal androgens, estrogen, and 
progesterone or, in the case of L702H, by glucocorticoids (Figure 5.2). These 
mutations can also convert anti-androgens into AR agonists. AR mutations are rarely 
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found in HNPC but are estimated to be present in about 15–20% of patients with 
CRPC (31). 
 
Ligand independent AR activation 
The expression of ARVs is increased in response to ADT and in resistant tumors, but 
can also be found in normal tissue. In these variants, truncation and exon skipping of 
AR mRNA results in a substantial or complete loss of the ligand binding domain, 
rendering some variants constitutively activated and androgen independent (Figure 
5.3A), for example, ARV7, the most common ARV found in PC. The expression of 
constitutively active ARVs is believed to be involved in CR transformation and in 
acquired resistance mechanisms to CR-targeted therapies such as the AR-targeting 
drugs abiraterone acetate and enzalutamide (Figure 3) (31). ARV7, the best studied 
ARV, has been show to regulate both AR-regulated genes and a unique set of AR-
independent genes, an indication of an overlapping but distinct role compared to full-
length AR in PC cells (79). 
Ligand independent AR activation in CRPC can also be achieved through crosstalk 
phosphorylation by downstream tyrosine kinases (Figure 5.3B), for example from 
signal transduction pathways form several growth factors, including insulin-like 
growth factor 1 (IGF-1), keratinocyte growth factor (KGF), epidermal growth factor 
(EGF) and HER-2/neu (80, 81). Furthermore, signal transduction by the neuropeptide 
neurotensin (NT) and gastrin releasing peptide (GRP) has also been reported to 
phosphorylate and activate the AR in the absence of androgens (82, 83). 
 
Intratumoral steroidogenesis and the utilization of adrenal androgens 
Medical or surgical castration reduces circulating levels of serum testosterone by 
>90%; however, physiologically significant amounts of intratumoral androgens 
remain after ADT in the prostate and in metastatic CRPC (79). A primary source of 
these residual (prostatic) androgens is the adrenal androgens DHEA-S, DHEA, and 
AD, which are not affected by ADT using GnRH antagonists and/or agonists (Figure 
2 and 3A). These precursors can be further converted into testosterone and DHT in 
pehripherial tissues (Figure 3B and 5.4B). In addition, intratumoral de novo 
biosynthesis from cholesterol might also be initiated to increase the pool of DHT. For 
this, the tumor cells upregulate enzymes for steroidogenesis, for example CYP17A1, 
ACKR1C3, SRD5A, and 17β-HSD, a mechanism that is commonly observed in 
CRPC (Figure 3 and 5.4A) (79). 
 AR bypass 1.3.5.2
AR bypass refers to the mechanism in which AR-targeted genes remain regulated, 
but without the involvement of the AR, and are instead regulated by a different 
hormone receptor. One example, observed in both cell culture and in clinical 
samples, is glucocorticoid receptor stimulation by glucocorticoid, which regulates a 
subset of AR-targeted genes in PC (Figure 5.5A) (31). 
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The glucocorticoid receptor and the AR share substantial homology within the DNA-
binding domain, which could explain the appearance of this mechanism. 
Glucocorticoids are normally administered together with abiraterone acetate during 
AR-targeted therapy, this in the form of prednisone, to decrease symptoms of 
mineralocorticoid excess, which might have an impact on this resistance mechanism. 
The progesterone receptor and the mineralocorticoid receptor are two other nuclear 
steroid hormone receptor family members with structural resemblance to the AR, and 
therefore are also potential candidates for AR bypass mechanisms in PC. 
The expression of progesterone receptor has been demonstrated in prostate tumor 
cells in some, but not all, studies, and a high level of progesterone receptor staining 
in primary PC tumors has been reported to be associated with clinical recurrence 
(31). 
 
 
Figure 5. Resistance mechanisms associated with the transition to CR growth and with acquired 
resistance to CR-targeted therapies. Most of these mechanisms are associated with restored and 
enhanced AR signaling, for example, through AR amplification (1), AR mutations (2), ligand-
independent AR activation (3), or through intratumoral steroidogenesis (4A). The AR also 
commonly becomes hypersensitive due to, for example, increased stabilization and nuclear 
transfer, while its transcriptional activity is enhanced and altered by the expression of various 
cofactors as well as through chromatin remodeling. Ligand-independent AR activation can be 
achieved through the expression of constitutively active ARVs (3A) or through cross-activation by 
other signaling pathways (3B). Furthermore, AR-targeted genes can be regulated trough bypass 
mechanisms (5A) where AR-response genes are alternatively activated by a different driver, for 
example, via glucocorticoid signaling. In addition, completely AR-independent mechanisms (5B) 
sometimes dominate, commonly in neuroendocrine PC (NEPC) and in PC stem cells, where other 
genes for growth and survival are transcribed and expressed than those that are under AR 
regulation. The illustration is reproduced and redrawn with inspiration from BJ Feldman et al 
(84). 
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 AR independent mechanisms 1.3.5.3
In these AR-independent tumors, growth and survival is stimulated by non-AR-
targeted genes and are activated by alternative drivers (Figure 5.5B). NE-like tumor 
cells, like normal NE cells, are known to express various growth and survival 
stimulating factors, for example, the neuropeptides NT and GRP (82, 83).  
1.4 NEUROENDOCRINE CELLS 
 The normal NE cell 1.4.1
NE cells can be found in epithelial linings throughout the body, including the 
gastrointestinal tract, respiratory tract, the urogenital system, and the skin. 
Furthermore, they are found in endocrine glands, such as the hypothalamus and the 
thyroid, and in exocrine glands, such as the prostate and the mammary glands (24). 
 
The origin of prostatic NE cells is still a matter of debate, but they are likely derived 
together with the basal and the luminal epithelial cells from a common endodermal 
pluripotent stem cell. Another suggestion is that the basal and the luminal cells have 
a common endodermal origin, while the NE cells instead are of neurogenic origin 
and are derived from migratory neural ectoderm (15, 24). Despite this uncertainty, it 
is believed that the prostate epithelium comprises a small number of tissue stem cells 
with basal-cell characteristics that are capable of tissue regeneration. Furthermore, it 
is clear that NE cells can transdifferentiate from luminal epithelial cells, giving rise 
to an NE-like cell type (15, 21, 52), thus mirroring the close relationship between the 
cells of the prostatic epithelium. 
The normal NE cell of the prostate is terminally differentiated, postmitotic, and AR 
negative, and hence androgen independent (21, 52). These cells express a mixed CK 
pattern of basal CK5 and luminal CK8 (22) and are further characterized by high 
resistance to apoptosis, partly due to their low rate of proliferation (21, 52).  
 Characterization and function  1.4.1.1
The NE cells are a normal component of both the glandular and ductal epithelium of 
the prostate, representing a minor cell population estimated to account for less than 
1% of the epithelial cells (85), and they are found at the highest density within the 
periurethral and the ductal regions (86). The normal NE cell displays a combination 
of neuronal and endocrine features, having a partly neuron-like morphology and an 
endocrine-like secretory mechanism. In the epithelium, the prostatic NE cells are 
scattered within the basal cell layer and exist in either an open or a closed form (24). 
The open cell type extends cytoplasmic processes toward the lumen thus sensing the 
prostatic secretions and the environment, while both the opened but mostly the 
closed form extends dendritic processes between adjacent cells (52) that are 
responsible for cell-cell communication both with surrounding epithelial cells and 
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with each other. In addition, both afferent and efferent nerves innervate the prostatic 
NE cell population (24).  
 
The NE cells are further characterized by the presence of cytoplasmic dense core 
granules of marked heterogeneity in size and form containing hormone peptides for 
storage and secretion, secreted either constitutively or in response to an incoming 
stimulus. Due to the wide diversity of these granules, as well as the diversity in 
secretory products produced by the NE cells, the NE cell population is believed to 
represent a number of subpopulations, each with its own set of secretory products 
and characteristic mode of regulation. Examples of NE secretory products include 
CHGA, NT, GRP, serotonin, parathyroid hormone-related protein (PTHrP), 
calcitonin, human chorionic gonadotropin (hCG), somatostatin, vascular endothelial 
growth factor, and glucagon (52). 
 
Although morphologically different from the other epithelial cells of the prostate, the 
NE cells can normally not be recognized only with histological examination, and 
they need to be identified through immunohistochemical staining for specific NE 
markers (85, 86). 
NE markers that are commonly used for identification include NSE (an isoenzyme), 
CHGA (a secretory product), neural cell adhesion molecule 1 (NCAM1 or CD56; a 
surface glycoprotein), and synaptophysin (SYP, a synaptic vesicle glycoprotein), 
which are expressed in most but not all NE cells (24, 51, 78). These markers are 
commonly also used to identify NE-like tumor cells both in vitro and in clinical 
samples, this with varying degree of correlation between focal NED and PC 
progression (24, 52). 
In clinical settings, synaptophysin is considered the most sensitive and CHGA the 
most specific NE marker, while neuronal NSE in recent years has been proven to be 
rather unspecific for NE and NE-like tumor cells (24, 51). 
 
The NE cells are involved in regulating the growth, survival, and differentiation of 
surrounding epithelial cells mainly through paracrine stimulation (21). In addition, 
the NE cells are involved in autocrine, endocrine, and neurocrine signaling 
mechanisms and are themselves under neural control (24). The function of NE cells 
is thus primarily to maintain normal prostatic differentiation and function, including 
secretory processes from the luminal cells (52), and might therefore during normal 
circumstances have a protective role against prostatic carcinogenesis. African-
American males are known to have a lower number of prostatic NE cells compared 
to the general population (24) and are also more prone to the development of PC (11, 
34). 
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 Neuroendocrine‐like tumor cells  1.4.2
During the progression of PC, there is commonly an accumulation of NE-like tumor 
cells within the prostate adenocarcinoma, especially in association with the transition 
to CR growth (87-90) and during the progression of CR disease (Figure 6), an 
increase that is accompanied by treatment resistance and poor prognosis (21, 87, 88).  
 
 
Figure 6. Morphological presentation of normal prostate epithelium (A) and high grade 
adenocarcinoma with accumulated NE-like tumor cells (B), stained for CHGA. During PC 
progression, there is a general de-differentiation with gradual loss of glandular structures. In 
parallel, there is increased NED as identified by the expression of NE markers such as CHGA. 
NED is generally considered to be correlated with tumor grade and aggressiveness/de-
differentiation Immunohistochemical staining of CHGA in primary prostate tissue (TURP 
specimen), photographed with a light microscope.  
 Neuroendocrine differentiation (NED) 1.4.2.1
Prostatic NE-like tumor cells are believed to arise through NED, which is a 
transdifferentiation from malignant luminal epithelial cells (Figure 6). The 
transdifferentiation pathway is supported by the fact that NED can be induced in 
vitro through steroid deprivation of PC cell lines with luminal characteristics as well 
as by the genetic resemblance between the NE-like tumor cells and luminal-derived 
cancer cells (21, 75). 
 
NE-like tumor cells thus display a mixture of luminal markers (e.g. luminal CK8 and 
CK18) and NE/neuronal markers and are different from, and should be distinguished 
from, the normal NE cell population that presents with basal or intermediate 
characteristics (21, 22, 52). Furthermore, the NE-like tumor cells express several 
proteins not found in normal NE cells, for example, BCL2 (an anti-apoptosis marker) 
and AMACR (a marker associated with PC, including NE-like tumor cells) (21). 
Although NE-like tumor cells express secretory neuropeptides and NE/neuronal 
markers, in clinical samples they sometimes lack typical cellular processes that are 
characteristic of normal NE cells, and instead have a morphology that is similar to 
A.  B. 
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the luminal-derived cancer cells (52). In vitro, however, steroid deprivation induced 
NED in androgen-sensitive PC cells, induces a morphological transformation toward 
a neuronal-like phenotype of tapering cell bodies and dendrite protrusions (Figure 7) 
(91, 92). 
The NE-like tumor cells are further characterized by a ceased proliferation and of 
androgen independence; no or low expression of the AR and of AR targeted genes, 
such as PSA (21, 52). 
 
 
Figure 7. In vitro steroid deprivation of the androgen sensitive PC cell line LNCaP is associated 
with NED, as represented by decreased proliferation, the upregulation of diverse NE/neuronal 
markers, and a neuron-like morphological transformation, i.e. tapering cell bodies and dendrite 
protrusions. Phase contrast imaging of LNCaP cell during basal conditions (FBS) and during 
steroid deprived conditions (DCC). 
 
Escape mechanism  
NED in PC is generally believed to represent an escape mechanism driven by the 
castration therapy and by AR inhibition (21, 75), and this is supported by 
observations of induced NED in response to androgen depletion in many preclinical 
studies (92-94) as well as increased NED after ADT in clinical studies (89, 95). 
Accordingly, accumulated NED within PC tumors has been correlated with CRPC, 
both its acquisition (87-90) and progression, including a poor clinical prognosis (87, 
96) ). However, there is little evidence for an independent impact of NED on 
progression (53). Accumulated NED has also recently been observed to be associated 
with AR–targeting therapies with enzalutamide (an AR antagonist) and abiraterone 
acetate (an androgen biosynthesis inhibitor) in CRPC (Figure. 3). The increased 
NED following abiraterone acetate or enzalutamide treatment is correlated with poor 
survival (76, 77), likely due to acquired resistance mechanisms. With the growing 
use of highly potent AR-targeting drugs like abiraterone acetate and enzalutamide, 
there is an expectation of increased treatment-related NEPC in the future, and this 
concern has resulted in an increased focus on the pathogenesis of NED (97). 
 
Cancer promotion 
NED is believed to play an active role in CRPC transition and growth, partly due to 
the secretion of different growth-promoting neuropeptides from the NE-like tumor 
cells, for example NT and GRP (98-100), both of which also have been found to 
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activate the AR in the absence of steroids(82, 83).The NE-like tumor cells are also 
highly resistant to apoptosis and to most chemotherapeutic and radiation therapies, 
partially due to their low rate of proliferation (97, 101, 102). Furthermore, the 
adaptive state of highly resistant and slowly proliferating NE-like tumor cells is 
generally believed to represent a temporary state, and NED is a reversible process 
(103), i.e. the NE-like tumor cells can differentiate back to a proliferating state at the 
end of treatment or at the time of recurrence or, as suggested by Abrahamsson et al 
(52), they can gain selected traits from the NE cells such as the secretion of different 
neuropeptides but still remain proliferative. 
 
Reprogramming 
It is evident that the process of NED relies on a network of transcriptional 
reprogramming, including epigenetic modifications (75, 104, 105), for example, the 
downregulation of repressor element-1 silencing transcription factor (REST, involved 
in chromatin remodeling) that is essential for the acquisition and maintenance of 
neuronal features (106-108), and the upregulation of the polycomb histone 
methyltransferase enhancer of zeste 2 (EZH2), which is associated with both CRPC 
(109, 110) and NED/NEPC (104, 105, 111). In recent years, it has also become 
evident that the NE-like tumor cells upregulate different stem cell markers, 
suggesting stem cell-like functions of these cells (75, 86, 106, 112). The process of 
NED might therefore be closely associated with dedifferentiation and 
reprogramming.  
 
Other alterations frequently associated with NEPC include the loss of tumor Other 
alterations frequently associated with NEPC include the loss of tumor suppressors 
RB1, PTEN, and TP53, mutations and amplification of MYCN (involved in the 
regulation of neural differentiation) and AURKA (involved in cell cycle regulation), 
upregulation of ASCL1 (a pro-neural transcription factor), activation of mitotic 
programs, and genomic instability (75, 78, 86, 113, 114). In addition, NE-like tumor 
cells are generally considered to be AR low/negative, although several recent studies 
have confirmed AR expression in a substantial fraction of NEPC as well as AR 
expression in mixed tumors of NEPC and conventional adenocarcinoma (75, 86). 
Although many interesting candidate drivers for NED and the development of NEPC 
have been proposed in recent years, for example, AURKA and MYCN, a targetable 
driver resulting in clinical survival benefits has so far not been identified (113, 115). 
A better understanding of the underlying biology of NED and NEPC is still required 
in order to efficiently identify further therapeutic targets.  
 Neuroendocrine PC (NEPC) 1.4.2.2
principal, all adenocarcinomas of the prostate, as well as the benign prostatic 
epithelium, have some degree of NE-marker positive cells, normally presented in a 
sparse and scattered appearance. In advanced HNPC, an accumulation of focal NE-
like tumors cells is a relatively common event, considered to occur in about 5–10%, 
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(85, 86, 116), while de novo pure NE tumors, like small cell prostate carcinomas 
(SCPC), are very rare at primary diagnosis (0.5-2%) (116-118). The incidence of 
both focal NED (88-90, 95) and SCPC (117, 119) are however more frequent in the 
CR stage of the disease. NEPC therefore mainly develops from adenocarcinoma and 
furthermore consists of a spectrum of subtypes ranging from conventional 
adenocarcinoma with accumulated NED to pure forms of NE tumors, of which SCPC 
represents the most aggressive form and is characterized by poorly differentiated, 
highly proliferative tumor cells with neuronal characteristics (53, 86, 117, 118). 
Furthermore, in the advanced stages, mixed tumors of conventional adenocarcinoma 
and SCPC can be observed (86) as well as clinical features of SCPC or “anaplastic” 
PC in morphologically heterogeneous CRPC (53). 
 
NEPC is characterized by aggressive and rapid disease progression, often with an 
atypical pattern of metastatic disease, including visceral metastases, and a low PSA 
serum level that is out of proportion in relation to the tumor burden (120). These 
tumors commonly display clear features of NED, including neuronal characteristics, 
but might sometimes display an aggressive AR-independent phenotype without 
features of NED, sometimes referred to as anaplastic PC and sometimes included in 
the term NEPC (75, 117, 120).  
Furthermore, according to autopsy studies, aggressive forms of NEPC have been 
considerably underestimated until rather recently, and NEPC is today estimated to be 
relatively common with up to 25% of lethal PC cases considered to be driven by 
NED(120). 
 
NEPC – diagnosis and treatment 
In the identification of NED, CHGA is the most commonly used and the most 
specific NE marker (85). However, CHGA is likely not optimal in defining NED due 
to the heterogeneous nature of NE tumor cells. There is also a lack of clear 
relationship between CHGA expression and tumor aggressiveness. Serum markers 
such as CHGA and/or NSE can be used for an initial screening but are not reliably 
high in all patients with increased NED or transformed NEPC (75, 120, 121). 
Optimally, several serum markers should be followed simultaneously, and metastatic 
tumor biopsies are of great value as well as the evaluation of circulation tumor cells. 
Furthermore, the NED process should be followed in response to novel treatments to 
better be able to predict treatment responses and for increased knowledge concerning 
ongoing resistance mechanisms. Lastly, new and better biomarkers are needed. 
 
NEPC has poor response to androgen modulation and AR-targeting therapies, with 
the most aggressive form, SCPC, being almost completely unresponsive. SCPC does, 
however, display frequent but short-lived responses to platinum-based 
chemotherapies, e.g. cisplatin (53, 120), but no more treatment options are available 
for this highly resistant patient group. There are, however, many ongoing preclinical 
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studies on different candidate targets, including targeted therapies against ARUKA, 
MYCN and PARP (113, 115, 122).  
Because NED is primarily considered to be a therapy-driven adaptive process to 
ADT and AR-targeting therapies, and because NE-like tumor cells are characterized 
by high resistance to most therapies (53, 97, 119, 120), a biomarker that could 
differentiate for the predisposition of NED before primary treatment would be highly 
valuable. 
1.5 MIDKINE 
 General background 1.5.1
Midkine (MDK) is a heparin-binding growth factor and cytokine that is involved in 
diverse biologic functions such as promoting survival, growth, migration, 
differentiation, and gene expression (123). 
 
MDK was discovered in 1988 as a retinoic acid response gene in embryonic 
carcinoma (124), and was further confirmed to be highly expressed in response to 
retinoic acid during embryogenesis, especially during the mid-gestation period, 
hence its name (mid-gestation – cytokine). MDK is downregulated around birth and 
is thus developmentally regulated. During embryogenesis MDK is involved in 
neurogenesis, EMT, mesoderm remodeling and stem cell renewal. The involvement 
of MDK in neurogenesis is integral to proper development, and MDK is a 
neurotrophic factor involved in neurite outgrowth and in the survival of neurons and 
neural progenitors (123, 125, 126). Pleiotrophin (PTN) is a structural relative of 
MDK, and together they comprise a small family of heparin-binding proteins. MDK 
and PTN share about 50% sequence homology and have very similar three-
dimensional protein structures. Furthermore MDK and PTN share receptors and are 
involved in similar activities, including fibrinolytic, anti-apoptotic, mitogenic, 
transforming, angiogenic, and chemotactic activities (127). MDK and PTN both 
display specific, but overlapping, expression patterns during neuronal development 
where PTN peaks after MDK, around birth (128). 
 
The importance of MDK and PTN for development has been confirmed through 
deficiency studies in mice where homozygous deletion of either Mdk or Ptn results in 
slight developmental abnormalities mainly associated with the neurological tissues. 
However, homozygous deletion of both Mdk and Ptn results in severe developmental 
abnormalities, including frequent prenatal death, reduced sized, a shorter life span, 
and female infertility due to impaired follicular maturation(123, 129, 130). MDK 
deficiency during development is therefore largely considered to be compensated for 
by PTN. 
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Both MDK and PTN are downregulated after birth. In the adult, MDK is expressed at 
negligible levels, and the expression is restricted to specific sites such as in the 
kidneys where very low levels are found. Because MDK is a secreted protein, low 
levels can also be found in body fluids such as serum, plasma, and urine (131). MDK 
is, however, induced and highly expressed during tissue repair as well as in many 
pathological conditions such as in inflammatory diseases and in most human 
carcinomas (123, 125, 127, 131). PTN also has very restricted expression in the 
healthy adult but sometimes is upregulated in association with human carcinoma. In 
general, however, MDK is expressed more intensely and in a wider range of human 
carcinomas than PTN (123, 127, 128). 
 MDK regulation and protein structure  1.5.2
The human MDK gene (MDK), located on chromosome 11 (site p11.2), is composed 
of four coding exons (130). Several splice variants have been reported at the mRNA 
level, of which at least two have also been detected as protein products – VA-MDK 
and tMDK. VA-MDK has two extra amino acids (valine-alanine) at the N-terminus, 
while tMDK lacks exon 3, which corresponds to the N-terminal domain (131). VA-
MDK is suggested to be naturally expressed simultaneously with conventional MDK 
in vivo, but a potential biological difference concerning activity and function 
compared to conventional MDK has so far not been found. It is, however, suggested 
that VA-MDK might represent a more stable product due to the importance of the N-
terminus in MDK stabilization and thus might have a longer half-life. tMDK has 
been reported to be tumor specific and to be associated with lymph node metastasis 
in clinical samples and with invasion in vitro (130). 
 
As mentioned above, MDK is induced by retinoic acid, and accordingly a retinoic 
acid response element (RARE) can be found in the MDK gene promoter region. 
Furthermore a hypoxia response element as well as an NF-κB binding site can be 
found within the promoters responsible for hypoxia (mediated by HIF1α) and NF-
κB-induced MDK expression, respectively (123, 130, 132). The promoter region also 
contains two binding sites for the Wilms tumor suppressor gene product (WT1), 
which is responsible for suppressing MDK expression (123) and loss function of this 
gene product in Wilms tumors is reported to account for the overexpression of MDK 
in these tumors (133, 134). NF-κB has been reported to induce MDK expression in 
PC, and the induction of MDK has been confirmed to support survival (135). 
Furthermore, the expression and activity of NF-κB has been associated with PC stem 
cells (136) as well as been described as a transcription factor associated with NED 
(137). 
 
Translation of MDK mRNA results in a low molecular-weight protein of 13-kDa that 
is rich in basic amino acids and cysteines. The MDK protein is composed of two 
structural domains, the N-domain (which is close to the N-terminus) and the C-
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domain (which is close to the C-terminus), and the C-domain contains two heparin 
binding clusters that are important for the biological activity of MDK. Spontaneous 
dimerization of two MDK proteins sometimes occurs and is considered essential for 
some MDK activities. The N-domain appears to be important for the stability of 
MDK and is also involved in the dimerization process (123, 130).  
 Cell signaling and biological activity  1.5.3
The biological activity of MDK is mainly executed through intracellular signaling, 
where MDK acts by binding to complexes of multiple transmembrane receptors (127, 
128). Due the promiscuous nature of MDK and the great number of available 
receptors, as well as due to alternative downstream signaling pathways, MDK has 
been implicated in a diverse range of biological processes. In addition to receptor-
mediated signaling, MDK also exerts some of its effects directly within the nucleus, 
and these activities are associated with the promotion of survival and with an 
increase in ribosomal RNA synthesis (130). However, exactly how these mechanisms 
are executed is still unknown. The MDK receptor, LDL receptor-related protein 1 
(LRP1), is however involved in the MDK nuclear translocation, through endocytosis 
of bound MDK. In the cytoplasm, internalized MDK interacts with the cytoplasm-
nucleus shuffle proteins nucleolin and laminin that translocate MDK to the nucleus 
(138, 139). 
 
Table 1 Receptors of MDK 
Receptors Gene symbol Activity 
Syndecan 1, 3 and 4 SDC-1, -3, -4 Neurite outgrowth (130, 140, 141) 
Glypcian 2 GLC2 Adhesion and neurite outgrowth (138, 142) 
Neuroglycan C NGC Neurite outgrowth (138, 142) 
Protein tyrosine 
phosphatase ζ PTPZ 
Migration (138, 142, 143) 
Abolished dephosphorylation of e.g β-catenin 
(138)  
Survival (130) 
LDL lipoprotein 
receptor-related 
protein 1 
LRP1 
Survival of neurons (130, 138, 144),  
Anchorage independent growth (138, 145) 
Nuclear targeting of MDK (139) 
Anaplastic lymphoma 
kinase ALK Cell growth (130, 146) 
Integrins;  
α4β1 and α6β1 
ITGA4, ITGA6, 
ITGB1 Neurite outgrowth, migration (142, 147) 
Notch 2 NOTCH2 EMT and drug resistance (130, 142, 148) 
The PTPζ, the syndecans, glypcian 2 and neuroglycan C are proteoglycans, the others are not.  
 
MDK has many identified receptors, but none so far are specific for the MDK/PTN 
family and many have a relatively low MDK binding affinity. It is therefore likely 
that MDK frequently binds to more than one component in the receptor complex in 
order to exert its function (130). MDK has, however, been confirmed to have a high 
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binding affinity towards both heparan sulfate and chondroitin sulfate chains in 
addition to heparin (a highly sulfated form of heparan sulfate). Several of the MDK 
receptors are therefore represented by proteoglycans in which the 
glycosaminoglycan portion is responsible for recognition and high-affinity binding 
of MDK (130, 142). For some of the receptors and proposed MDK-mediated 
activities see Table 1.  
 
Downstream signaling pathways that are important for MDK signal transduction 
include PI3K/AKT, MAPK, ERK1/2, NCID (the activated intracellular part of Notch 
2), Src, PKC, and Paxilin, and transcription factors that are affected by MDK 
signaling include NF-κB, Hes-1, and JAK/STATs (130). For the promotion of 
survival, MDK-dependent suppression of caspase-3 and the activation of Bcl-2 have 
been observed, while activities associated with differentiation, neurite outgrowth, and 
migration involve cytoskeletal remodeling (130, 138). Signaling via ALK is involved 
in increased proliferation, while signaling via Notch 2 is involved in EMT and in 
drug resistance mechanisms (130). 
 MDK in cancer 1.5.4
As mentioned above, MDK is induced and upregulated in a wide array of 
pathologies, including inflammatory diseases such as rheumatoid arthritis and 
multiple sclerosis as well as in most human carcinomas. MDK is also upregulated 
during tissue generation and tissue repair as well as during hypoxia and in 
association with high blood pressure (123, 125, 130, 142). 
 
The association with MDK and cancer is constantly getting more support, and the 
role of MDK in cancer and the applicability of MDK as a therapeutic target has 
gained increased attention in recent years. At present, MDK is reported to be 
overexpressed in over 20 different human carcinomas (127, 131), including PC (135, 
149, 150), and an elevated MDK level in the circulation has been correlated with 
poor clinical outcome in various human carcinomas (131, 151-155). Collectively, 
MDK is considered to be a potential tumor biomarker (131, 151-155) and diagnostic 
tests, measuring circulating MDK is currently entering the clinic for several different 
carcinomas (131). Furthermore, MDK is also suggested to be a potential treatment 
target in some human carcinomas (154, 156-162).  
 
In some human carcinoma, including PC, MDK is considered to be an early 
biomarker, detected already in premalignant lesions (127). As a progression 
biomarker, the early induction of MDK during cancer progression is an important 
feature because it allows for the early detection of cancer development and can 
potentially be used to discriminate between aggressive and non-aggressive cancers.  
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 Biological function and impact  1.5.4.1
MDK, being a pleiotropic protein, has been associated with many cancer-promoting 
features in different human carcinomas, including proliferation (163, 164), survival 
(165), transformation (166), angiogenesis (167, 168), and metastasis (169, 170), and 
thus it is considered to play an active part in tumor development and progression and 
to be associated with aggressiveness. In PC, MDK has been associated with cell 
survival (135) and proliferation (171). MDK has also been associated in numerous 
studies with resistance to chemotherapy (154, 156-161). For example, it possess a 
cytoprotective role against doxorubicin (interferes with DNA replication) in 
neuroblastoma (159), while it has varying effects with platinum-based 
chemotherapies cisplatin (interferes with DNA repair) in different cancer forms. In 
most carcinomas studied so far, MDK expression has been associated with a 
cytoprotective role against cisplatin (154, 156, 160, 161), but in some studies MDK 
expression has instead been associated with enhanced cytotoxicity of cisplatin (157, 
158). The possible suppressing or enhancing effect of MDK on platinum-based 
chemotherapy in PC remains to be determined, but it opens up an interesting area for 
exploration because platinum-based chemotherapies are the treatment of choice for 
aggressive NEPC (53, 122). Collectively, however, MDK seems to have a strong 
value as a therapeutic predictor, at least regarding cisplatin, as well as representing a 
possible target in combination with cisplatin therapy for certain patient groups. 
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2 AIMS 
The overall aim of this thesis was to evaluate the role and impact of MDK in PC, 
with a specific focus on the CR state of the disease and on castration-induced 
transformations, including NED.  
 
 
 
The specific aims are outlined as follows: 
 
 
 To evaluate the expression of MDK in relation to PC progression 
and NED 
 
 To investigate the function of MDK and its dependence on 
androgens and/or AR-signaling  
 
 To evaluate the clinical value of MDK as a biomarker in advanced 
prostate cancer  
 
 To study MDK in relation to castration-induced transformation in 
PC as well as its relation to the CR-state  
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3 MATERIAL & METHODS 
In this thesis, the effects of castration on PC pathogenesis and progression, ultimately 
leading to CRPC transformation, including NED and other resistance mechanisms, 
have been studied through in vitro experiments and through the analysis of diverse 
clinical materials. In the studies conducted in this thesis, the primary focus has been 
on the expression and function of MDK and its relation to AR signaling, 
dedifferentiation, and NED. 
3.1 CLINICAL SAMPLES 
For our studies of PC in humans, clinical samples in the form of primary prostatic 
tissue and plasma were evaluated. Prostatic tissue included transurethral resection of 
the prostate (TURP) specimens, needle biopsies, and tissue from prostatectomies. 
The use of patient material was approved by the local ethics committee. 
 Transurethral resection of the prostate (TURP) (Paper I) 3.1.1
Archival TURP specimens were used to evaluate the expression of MDK in early 
compared to advanced primary PC as well as to evaluate any association of MDK 
with NED. The TURP specimens were collected from patients with early, low-risk 
HNPC (T1b, n = 29) and patients with progressed CRPC (n = 24). For the evaluation, 
MDK, the NE marker CHGA, and the neuronal marker tubulin-beta III (TUBB3) 
were stained on sequential sections with immunohistochemistry (IHC) techniques, 
and the expression pattern was compared between groups and between markers. 
Triple immunofluorescence (IF) was performed on a selection of specimens. 
It should be noted that the CRPC TURP specimens represent tumors with local 
progression, a rather uncommon event in PC where tumor relapse normally occurs at 
metastatic sites. 
 Prostatectomies (Paper III) 3.1.2
Archival prostatectomy specimens were used to evaluate the expression of MDK and 
the NE marker CHGA in primary PC undergoing radical prostatectomy and 
randomized to 3 months of neoadjuvant ADT or not (172). 
Forty specimens from the treatment arm and 52 specimens from the control arm were 
used in the present study (cohort 3, paper III). For the evaluation, MDK and CHGA 
were stained on sequential sections with IHC, and the expressions were compared 
between treatment groups. 
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The patients had localized, intermediate-risk PC (T1b-T3a, N0, M0, G1-3) and were 
sampled prior to treatment initiation. For clinicopathological characteristics of the 
patients, see paper III, cohort.3. 
 Prostate needle biopsies (Paper III) 3.1.3
Archival needle core biopsies were used in paper III to evaluate the expression of 
MDK in primary PC tumors and over the course of PC progression after ADT. The 
patients had locally advanced or metastatic PC with a PSA level > 80 ng/ml prior to 
the initiation of ADT. For clinicopathological characteristics of the patients, see 
paper III, cohort.2. 
The primary tumor biopsies were sampled from patients at baseline (n = 45), 
approximately 3 months post-ADT (n = 26), and at relapse into CRPC (n = 11). The 
specified n represents the specimen numbers used in the study. For evaluation, the 
biopsies were stained for MDK with IHC, and the expression was evaluated between 
the groups. 
It should be noted that the time point for CRPC relapse was defined based on clinical 
progression as metastases or failure in PSA control, making the CR status of the 
prostate tissue a bit uncertain. However, the biopsies were evaluated by a pathologist, 
and viable cancer cells with only weak signs of regression were detected in the 
majority of the 11 cases. 
 Plasma (Paper III) 3.1.4
Plasma samples from two independent patient cohorts were used to evaluate the level 
of circulating MDK during PC progression after ADT. The inclusion of patients in 
cohort 1 (n = 40) and cohort 2 (n = 51) occurred prior to the initiation of ADT and 
included patients with locally advanced or metastatic PC with a PSA level > 80 
ng/ml. For the clinicopathological characteristics of the patients, see paper III. 
 
The plasma was collected at baseline, prior to the initiation of ADT, and at different 
progression time points post-ADT. For evaluation, MDK plasma levels were 
assessed with enzyme-linked immunosorbent assay (ELISA). In addition, plasma 
from a small control group (n = 6) of patients with low-risk tumors (T1c, NX, M0, 
GS < 7, and PSA level < 10 ng/ml) were also analyzed. The resulting MDK 
concentrations were compared within patient cohorts (over the course of progression) 
and against the controls (baseline levels; pre-ATD). 
3.2 IN VITRO STUDIES  
For in vitro studies on PC biology and progression, the androgen-sensitive human PC 
cell line LNCaP (Lymph Node Carcinoma of the Prostate), FGC (fast-growing 
clone) was used as a model in studies at basal conditions (with steroids) and under 
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castrated conditions (without steroids). In addition, two LNCaP-derived, castration 
resistant (CR) sub-lines, LNstarv.1 (LNCaP starvation 1) and LNstarv.2 were used 
to characterize the process of CRPC transition and for studies on the CR state. 
 
The LNCaP cell line was originally established from a lymph node metastasis from a 
CRPC patient (173) and was obtained from the American Type Culture Collection 
(Rockville, MD, US).  
LNCaP is one of the most common androgen-sensitive cell lines used in PC research 
(31), and the cells express both AR and PSA. However, these cells possess a mutated 
AR in which the ligand binding domain harbors a T877A mutation making the AR 
responsive to other steroid hormones than androgens, for example, progesterone and 
estradiol (174, 175). AR mutations are common in CRPC, and the T877A mutation 
found in LNCaP cells is one of the most common AR mutations encountered in 
clinical samples (31). However, due to this mutation, the LNCaP model can only 
represent PC that harbors this or a similar mutations resulting in a promiscuous AR, 
and this is a limitation in the present studies.  
In addition to LNCaP, a few other androgen-sensitive PC cell lines have been 
established and are used in the field of PC research, for example, VCaP and LAPC4 
cells, both of which, unlike LNCaP, possess a wild-typeAR (31, 174). Comparative 
studies to the present LNCaP-based studies, using one or both of these wild-type AR 
cell lines, would be valuable. 
For all experiments, including basal conditions e and short- and long-term steroid 
deprivation, LNCaP cells between passages 11 and 13 were used, and cells were 
tested regularly and found to be free of mycoplasma. 
 Cell culturing  3.2.1
 Baseline studies of LNCaP (Papers II and IV) 3.2.1.1
For baseline studies (with steroids) of LNCaP the cells were maintained in phenol 
red-free RPMI 1640 culture media, modified according to the manufacturer’s 
recommendation and supplemented with 10% fetal bovine serum. LNCaP cells were 
also exposed to the AR-targeting drug enzalutamide and to DHT administration 
under both basal (FBS) and steroid-deprived conditions 
 Short‐ and long‐term steroid deprivation of LNCaP (Papers II and IV) 3.2.1.2
For studies of LNCaP under steroid-deprived conditions (without steroids), the cells 
were exposed to both short-term (4, 8, 10, 16, and 20 days) and long-term (over 1 
year) steroid deprivation. In steroid-deprived conditions, the cells were maintained in 
LNCaP basal medium supplemented with 10% steroid-depleted serum (DCC; 
dextran-charcoal-treated (DCC)-FBS) instead of complete serum (FBS).  
LNCaP grown in DCC were also exposed to the AR-targeting drug enzalutamide and 
to steroids in the form of DHT. 
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In experiments of short-term steroid deprivation, the effect of castration during the 
initial phase of adaptation and NED was studied. In long-term steroid-deprivation 
experiments, the stepwise progression of LNCaP into a CR) including the NE phase 
was studied.  
 
FBS versus DCC  
The method of using FBS versus DCC-containing media for simulating basal versus 
steroid-deprivation conditions is a standard procedure in the field of PC research, but 
this entails a source of uncertainty due to the “unspecific” content of serum as well as 
a possible difference between FBS and DCC in addition to the depleted steroids. A 
preferable method would have been a well-controlled complete serum-free 
complement with and without the addition of androgens in the form of DHT. 
 Generation of LNStarv.1 and LNStarv.2 (Paper IV) 3.2.1.3
In two independent experiments, long-term steroid deprivation generated two 
LNCaP-derived “castration-resistant” sublines, LNstarv.1 and LNstarv.2. The 
characterization of the terminal CR state of LNstarv.1 and 2, as well as the 
characterization of the whole progression course, including the preceding NE phase 
and colony-forming phase is an ongoing project.  
LNCaP cells from passage 11 were used when initiating LNstarv.1, and LNCaP cells 
from passage 12 were used when initiating LNstarv.2. Split (SP) 0 represents the 
initial cell seed, and SP1 represents the first de-attachment during the steroid 
deprivation timeline. LNstarv.1 was terminated in association with SP22 after 541 
days of steroid deprivation, and LNstarv.2 was terminated in association with SP17 
after 362 days of steroid deprivation. 
 
In both experiments, the morphological transformation was followed and 
documented in each passage and throughout the entire steroid deprivation timeline. 
Cells for mRNA and protein evaluation as well as for freeze sampling were collected 
at each cell split. In addition, DNA and conditioned media were collected at each 
passage in the second experimental setup (LNstarv.2), but these have not yet been 
analyzed. 
The morphological phenotypes that were associated with the different phases were 
similar, but not completely consistent, between LNstarv.1 and LNstarv.2, and 
furthermore LNstarv.1 needed a longer time within both the NE phase and the 
colony-forming phase before transition. These differences are likely due to different 
DCC products used in LNstarv.1 versus in LNstarv.2 (the DCC used for LNstarv.1 
was discontinued), where LNstarv.1 most likely been grown under a more stringent 
steroid deprivation, which is supported by observed differences in gene expression 
levels. 
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 Cell experiments on LNstarv.1 and LNstarv.2 (Paper IV) 3.2.2
Separate experiments along the transformation timeline were mainly performed with 
LNstarv.2 cells, which is a limitation in the present study. However, cells from both 
sublines from each cell passage have been frozen, and for the continued 
characterization of these cells we are planning to use these samples to compare 
morphologies and properties. Furthermore, experiments might be repeated with both 
sublines in parallel. 
 AR‐targeting (Paper IV) 3.2.2.1
For AR-inhibition experiments, 1–10 μM enzalutamide was included in the 
experimental media in the different experimental setups. For experiments including 
enzalutamide, the corresponding concentration of DMSO was used as the vehicle 
control.  
 Reversibility experiments (Papers II and IV) 3.2.2.2
Reversibility of the transformation process was analyzed through the re-introduction 
of steroids at different time points along the transformation timeline. Androgens were 
administrated in the form of steroid-containing media (FBS), DHT supplement, and 
conditioned media from LNCaP cells grown in the presence of steroids.  
LNstarv.1 cells were analyzed in the NE phase and the colony-forming phase with 
FBS administration, while LNstarv.2 cells were analyzed in the NE phase and the 
colony-forming phase as well as in the CR state with FBS, DHT, or condition media 
administrations. 
For experiments with DHT, the corresponding concentration of ethanol was used in 
parallel as the vehicle control. 
Furthermore, the cells were exposed to the AR antagonist enzalutamide during 
steroid re-introduction in order to assess the influence of the AR under these 
conditions. 
 De‐differentiation experiment (Paper IV) 3.2.2.3
To further analyze the de-differentiation process and stem cell properties of long-
term steroid-deprived LNCaP cells, LNstarv.2 cells from both the colony-forming 
phase and from the early CR state were exposed to growth in neuronal stem cell 
media with well-controlled serum-free supplements (DMEM F12 supplemented with 
B27 without retinoic acid, and bFGF), which also represented conditions of stringent 
steroid deprivation.  
After passaging, cells were re-seeded on both standard and poly-L-lysine-coated 
culture plates in order to analyze their adhesive properties and morphology. The cells 
were also subjected to the AR antagonist enzalutamide on order to assess the 
influence of the AR under this condition. 
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 Cell transfection – midkine silencing (Papers II and IV)  3.2.3
To determine the function of MDK in PC, we silenced MDK in LNCaP cells under 
both basal and steroid-deprived conditions (5 days of propagation). The cells were 
thereafter terminated 6 days post-nucleofection. 
 
The MDK knock-down experiments were performed through electroporation using a 
Nucleofector 2b device and the Nucleofector Kit R (Lonza) according to the 
manufacturer’s recommendation for LNCaP cells. The siRNA targeting MDK 
(siMDK, s8625) and a non-targeting control siRNA (siNEG, 4390846) were both 
from Ambion Silencer Select. The siRNA was chosen based on its performance 
among three different siRNAs targeting MDK and two non-targeting control 
siRNAs. Performance testing included a verified minimal MDK silencing effect on 
pleiotrophin (PTN, a structural relative to MDK) expression. 
Transfected cells were seeded on poly-L-lysine-coated plates according to the 
manufacturer’s recommendation, and the transfection efficiency was evaluated on 
both the mRNA (Q-PCR) and protein level (western blot).  
 
It should be noted that there was no obvious morphological change in siMDK 
compared to siNEG cells under steroid-deprived or basal conditions; however, slight 
morphological differences were seen in both the siMDK and siNEG cells compared 
to parallel untransfected control cells (e.g. increased cytoplasmic vacuoles). 
Furthermore, all steroid-deprived cells, siMDKs, siNEGs, and control cells grown on 
poly-L-lysine-coated plates had a somewhat less pronounced NE morphology 
compared to cells cultured on uncoated culture plates. The difference in MDK 
expression between siNEG and control cells was, however, in a similar range.  
Taken together, the results imply that the poly-L-lysine coating might affect the 
morphological NE transformation and that the invasive nature of the transfection 
process itself has an impact on the cell phenotype. 
To further evaluate the function of MDK in PC, it would be highly valuable to 
analyze the effect of MDK loss with the use of stable MDK-silenced cells, in contrast 
transient MDK-silencing using siRNA, as well as through the administration of an 
MDK inhibitor, for example, a neutralizing peptide. Furthermore, the effect should 
be analyzed in additional models of androgen-responsive PC, for example, in VCaP 
and LAPC4 cells, due to the heterogeneity in PC. 
3.3 FUNCTIONAL ANALYSIS 
To assess the performance and the functionality of MDK in LNCaP and LNstarv.2 
cells, functional analyses in the form of proliferation and survival measurements was 
performed during both basal and different experimental conditions. More 
specifically, proliferation and survival were assessed in response to AR-targeting 
(LNCaP and LNstarv.2 cells), during steroid re-introduction (LNstrav.2 cells) and 
 
Anna Nordin 
37 
during de-differentiation with neural stem cell media (LNstrav.2 cells) as well as 
during MDK silencing experiments (LNCaP cells). 
 Proliferation (Papers II and IV) 3.3.1
Proliferation was evaluated with a BrdU incorporation assay (Cell Proliferation 
ELISA; Roche Applied Science). 
 Survival (Papers II and IV) 3.3.2
Survival was assessed from fluorescent measurements generated from a specific 
protease that is restricted to intact and viable cells (Apo-Tox-Glow Triple Assay; 
Promega). 
3.4 RNA ANALYSIS 
 RNA and cDNA preparation (Papers II and IV) 3.4.1
Total RNA from cultured cells, pelleted or directly lysed when possible, was purified 
with an RNeasy Mini Plus Kit (Qiagen) in accordance with the manufacturer’s 
instructions. RNA concentrations and purity were determined spectrophotometrically 
(NanoDrop), and RNA intended for microarray analysis was quality checked using a 
Bioanalyzer (Agilent 2100). 
cDNA was prepared by reverse transcription of total RNA using VILO Superscript 
III (Invitrogen) according to the manufacturer’s instructions. 
 Quantitative Real Time Polymerase Chain Reaction (Paper II, IV) 3.4.2
Quantitative Real Time Polymerase Chain Reaction (Q-PCR) was performed with an 
ABI Prism 7500 Fast Sequence Detector (Applied Biosystems) for the analysis of 
individual TaqMan Gene Expression Assays and for TaqMan Array Gene Signature 
plates, and the analysis of microfluidics cards was performed on a 7900HT Fast 
Real-Time PCR System (Applied Biosystems). 
 Gene expression assays and gene signature plates (Paper II and IV) 3.4.2.1
For mRNA expression evaluation and verification, individual TaqMan probes were 
used (gene expression assays, Applied Biosystems). For paper II, a panel of TaqMan 
probes was used, including probes directed toward the AR, different NE/neuronal 
and dedifferentiation markers, and MDK. For paper IV, verification of candidate 
genes is ongoing, and of these many major targets have already been validated, 
including MDK, PSA, AR, and many NE/neuronal markers in both LNstarv.1 and 
LNstarv.2 cells. The data were analyzed according to the ΔΔCt method for relative 
mRNA quantification and were normalized to 18S or the average expression of three 
housekeeping genes – TBP, POP4, and CASC3. 
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TaqMan array gene signature plates, including Human Androgens (#4418741) and 
Human Stem Cell Pluripotency (#4418722), were used for initial screening after 
candidate genes in LNstarv.1 and LNstarv.2 split samples. The 96-well gene 
signature plates were pre-loaded with 96 TaqMan probes, including 4 endogenous 
controls. 
 Microfluidics (Paper IV) 3.4.3
Customized 384-well Microfluidic Cards for TaqMan Q-PCR (Applied Biosystems) 
were pre-treated with 96 specially selected TaqMan probes (TaqMan Gene 
Expression Assay) in duplicate, and these were run with selected samples from 
LNstarv.1 (SP1, SP2, SP3, SP4, SP5, SP6, SP7, SP8, SP10, and SP13) and LNstarv.2 
(SP1, SP4, SP7, SP10, SP13, and SP17), with one sample per microfluidic card. In 
addition, as a reference, LNCaP cells grown under basal conditions (FBS: 2 and 
2+12 days) and subject to short-term steroid-deprivation (DCC, 12 days) were also 
analyzed by microfluidics assay. 
The microfluidics cards were run at the Genomics Core Facility at Gothenburg 
University, Sweden. For all samples in run 1 (LNstarv.1, including references) and 
for all samples in run 2 (LNstarv.2, including references), a common threshold for all 
genes was set. Data were thereafter analyzed according to the ΔΔCt method for 
relative mRNA quantification and were normalized to the average expression of two 
housekeeping genes – 18S and CASC3.  
 cDNA microarray and analysis (Paper II) 3.4.3.1
Alterations in gene expression in LNCaP cells in response to MDK silencing were 
evaluated through whole-genome expression microarray analysis (Human Gene 2.0 
ST, Affymetrix) under both basal conditions (FBS) and during the early phase of 
steroid deprivation (DCC). 
RNA processing, GeneChip hybridization, scanning, and data pre-processing 
(normalization) were performed at the Genomics Facility SCIBLU, Lund, Sweden.  
The data were filtered to delete probe sets displaying signal intensities below 50 in 
all samples and then were log 2 transformed. The gene expression for siMDK was 
compared to the expression for siNEG under basal conditions and in steroid-deprived 
conditions (see the statistical section for further information). 
3.5 PROTEIN ANALYSIS  
 Protein preparation (paper II and IV) 3.5.1
Total protein from cultured cells, were prepared through cell lysis (direct when 
possible or of pre-pelleted cells), using Cell LyticM lysis buffer (C2978-50, Sigma-
Aldrich) supplemented with protease (Complete Mini) and phosphatase (PhosStop) 
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inhibitors from Roche Diagnostics. Protein concentrations were determined by BCA 
Protein Assay Kit (Pierce Chemical). 
 Western blotting (paper II) 3.5.2
Protein samples (15–20 µg) were separated according to size on 4–12% Bis-Tris 
gradient gels (Invitrogen) under reducing conditions and subsequently transferred to 
polyvinyldifluoride (PVDF) membranes using an i-Blot gel transfer system 
(Invitrogen). The membranes were incubated in 2% blocking solution (GE 
Healthcare) followed by incubation with primary antibody and subsequent incubation 
with horseradish peroxidase (HRP)-labeled secondary antibody. The 
immunoreactions were detected using the ECL Advanced Western Blotting 
Detection System (GE Healthcare) and visualized with a LAS4000 CCD camera. 
Primary antibodies used in paper II were directed against AR, PSA, NE markers, and 
MDK. As a loading control, an antibody against beta-actin was used (Sigma).  
 Enzyme‐linked immunosorbent assay (ELISA) (Paper III) 3.5.3
The plasma level of MDK was evaluated with ELISA for human MDK (Cellmid 
Ltd.) in patient samples during the course of PC progression, before and after ADT 
(cohort 1 and cohort 2, paper III). As a reference, plasma MDK was also evaluated in 
a patient group with low-grade localized PC.  
The ELISA procedures and calculations were performed according to the 
manufacturer’s instructions.  
 Immunocytochemistry (ICC) (Paper II and IV)  3.5.4
ICC for AR localization studies was performed on fixated LNCaP cells from basal 
and castrated conditions as well as on LNCaP-derived CR-subline LNstarv.2 cells. 
ICC was performed with the Vectastain Elite ABC kit (Vector Laboratories), starting 
from the endogenous peroxidase blocking step and proceeding according to the 
manufacturer’s protocol. Primary antibody labeling was performed with an anti-AR 
antibody (sc-7305, Santa Cruz Biotechnology), and as a negative control ICC was 
performed in the absence of primary antibody and with a corresponding isotype 
control. 
 ImmunoImmunohistochemistry (IHC) (Paper I and III) 3.5.5
IHC was used in paper I to evaluate MDK, CHGA, and TUBB3 expression in TURP 
specimens of low-risk HNPC and progressed CRPC. In paper III, IHC was used to 
evaluate the expression of MDK and CHGA in prostatectomies with or without 3 
months of ADT (cohort 3, paper III) and for the evaluation of MDK expression in 
primary biopsies during PC progression before and after ADT (cohort 2, paper III).  
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IHC of the TURP specimens and the prostatectomies was performed using the 
Vectastain Elite ABC kit (Vector Laboratories, Inc.), while the IHC of the biopsies 
was performed using the EnVision FLEX System (Dako) according to the 
manufacturer’s protocols. Primary antibodies were anti-MDK (5479-100, BioVision, 
Inc.), anti-CHGA (KL2H10, Neomarkers), and anti-TUBB3 (TUJ1, Convance). For 
information concerning antibody concentrations and incubations, see papers I and III. 
As negative controls, IHC was performed in the absence of primary antibodies. 
 Immunofluorescence (IF) and confocal imaging (Paper I and II) 3.5.6
In paper I, triple IF was performed on a selection of TURP specimens to determine if 
the observed co-expression patterns of MDK, CHGA, and TUBB3 in CRPC tumors 
were co-localized in the cells. In paper II, MDK and TUBB3 double IF was 
performed of fixated LNCaP cells cultured under basal and steroid-deprived 
conditions to evaluate their expression pattern and co-localization. 
 
Double IF ICC and triple IF IHC procedures were based on the Vectastain Elite ABC 
kit (Vector Laboratories, Inc.) using protocols for ICC and IHC, respectively (for 
details, see paper I and II), and they were performed by simultaneous labeling of 
primary antibodies followed by simultaneous detection with fluorophore-conjugated 
secondary antibodies. After primary and secondary labeling, the coverslips (fixated 
cells) or sections were washed, air dried, and mounted with Prolong Gold anti-fade 
with DAPI (Invitrogen). Negative and cross-reactivity controls were performed, 
respectively, by omitting primary antibodies and by staining with mismatched 
antibody couples in single IF labeling. 
Primary antibodies were directed against MDK, CHGA, and TUBB3-targeted, and 
the primary antibodies targeted by isotype-specific fluorophore-conjugated 
secondary antibodies (Molecular Probes, Invitrogen). For further information 
concerning antibodies, concentrations, and incubations, see papers I and II.  
 
Immunofluorescent confocal imaging was performed through sequential scanning 
using an inverted Zeiss LSM 510 META microscope (Carl Zeiss) equipped with a 
63/1.4 oil NA objective at the Centre for Cellular Imaging, Sahlgrenska Academy, 
University of Gothenburg. Merged images were obtained and processed using 
ImageJ software (http://rsb.info.nih.gov/ij) (for further details, see papers I and II). 
3.6 EVALUATION OF IMMUNOSTAINING  
 Quantitative IHC evaluation (Paper I and III) 3.6.1
Quantitative IHC evaluation was performed for MDK, CHGA, and TUBB3 staining 
of TURP specimens in paper I, for MDK and CHGA staining of prostatectomies in 
paper III, and for MDK staining of biopsies in paper III. 
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The staining was evaluated using a semi-quantitative scoring system combining the 
proportion of positive tumor cells and staining intensity in the malignant areas of 
each specimen. The proportion of positive cancer cells was scored as 0 = <5%, 1 = 
≤33%, 2 = ≤66%, and 3 = > 66%, and the intensity was scored as 0 = no detectable 
signal, 1 = weak staining, 2 = moderate staining, and 3 = strong staining. For the 
biopsy scoring, a fourth grade was used for both proportion (>90%) and intensity 
(very strong staining). 
 Qualitative comparative IHC evaluation (Paper 1) 3.6.2
In the CRPC TURP specimens (paper I), there was a strong association of MDK with 
both CHGA and TUBB3 staining in terms of both the staining appearance and the 
amount of co-expression. Thus we performed a comparative evaluation of MDK, 
CHGA, and TUBB3 in the TURP specimens. In this evaluation, we compared the 
association of double and triple co-expression between HNPC and CRPC tumors and 
between the staining appearances of general and scattered. 
 
For this analysis, individual hotspot areas were analyzed on serial sections stained for 
all three markers, and these were scored as positive or negative in the corresponding 
area/structure. The positive staining was furthermore characterized as general or 
scattered, and the distribution of co-expressing hotspots (single, double, and triple 
expressions) were compared between CRPC and HNPC tumors as well as between 
the general and scattered hotspot categories (see paper I for further information). 
3.7 STATISTICAL ANALYSIS  
Statistical analysis was carried out using the SPSS version 19.0 (paper II) and version 
23.0 (papers II and III) for Windows software. For all tests, p ≤ 0.05, p ≤ 0.01 and p 
≤ 0.001 were considered significant, if not otherwise stated. 
 
Statistics in paper I concerned the evaluations of the immunostainings. The Mann–
Whitney U-test was used to analyze differences in semiquantitative scores between 
two independent groups (HNPC vs. CRPC). Co-expressing hotspots from the 
comparative evaluations were analyzed as distributions of categorical variables using 
Fisher’s exact chi-squared test, and comparisons were made between marker 
expressions (single, double, or triple expression) and group (CRPC vs. HNPC or 
general vs. scattered staining). Bonferroni correction (α´= α/m, where m = the 
number of performed tests) was used for multiple testing. 
 
Statistics in paper II concerned calculations of microarray data, comparing 
functionality and the gene expression for siMDK with that for siNEG under basal 
conditions (with steroids, FBS) and under castrated conditions (DCC) in LNCaP 
MATERIAL & METHODS 
42 
cells. The difference in gene expression was analyzed with Significance Analysis of 
Microarrays using the TMEV v4.0 software. The false discovery rate (q-value = 
adjusted p-value) was set at q = 0%, and the genes were ranked according to fold 
change. The fold change cut-off was set at 1.4 for changes in FBS, while all altered 
genes are shown for castrated conditions in DCC. 
Gene ontology analysis was performed on differently expressed genes in FBS using 
the Database for Annotation, Visualization and Integrated Discovery (DAVID) tools 
(http://david.abcc.ncifcrf.gov/). 
Statistical calculations of differences in proliferation and in viability between siMDK 
and siNEG in FBS and in DCC were analyzed with the unpaired t-test. 
 
Statistics in paper III concerned calculations on patient samples, group comparisons, 
correlations, and prognostic calculations. 
The Mann–Whiney U-test was used to compare protein expression between non-
related groups, and Wilcoxon’s signed-rank test was used to compare protein 
expression between related groups. Spearman’s rho correlation was used to analyze 
bivariate correlations of prognostic factors. 
The Kaplan–Meier method with log rank statistics and univariable Cox (proportional 
hazards) regression analysis were used to estimate the unadjusted association of 
MDK and of all prognostic factors with cancer-specific survival (CSS) respectively.  
Multivariable Cox regression analysis of selected variables was performed to assess 
adjusted associations with CSS. The influence of plasma MDK in different models 
was evaluated using likelihood ratio tests of nested models comparing the overall p-
value of the full vs. the reduced model. The best prognostic parameter/model for CSS 
was assessed through stepwise backward and forward multivariable procedures. The 
prognostic value of plasma MDK was further evaluated and confirmed with 
nonparametric receiver operating characteristics curve analysis, analyzing the 
discriminative power of MDK levels for a short vs. a long CSS time (mean months). 
 
No statistical analysis has yet been performed in paper IV. 
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4 RESULTS AND COMMENTS 
4.1   Midkine is associated with neuroendocrine differentiation in 
castration resistant prostate cancer (PAPER I) 
 
The study for Paper I was designed in light of the evidence for MDK’s association 
with cancer and the lack of information concerning its involvement and expression 
pattern in PC. Furthermore, we took into consideration earlier results from our group 
showing that MDK is upregulated in the CR cell line LNCaP-19 compared to its 
androgen-responsive parental cell line LNCaP (176).  
The aim of the study for Paper I was thus primarily to evaluate the expression of 
MDK in PC by comparing the expression of MDK protein in low-risk (localized, 
T1b, stage II) HNPC) to the expression in CRPC. The evaluation of MDK expression 
was performed in an archival material of transurethral resection of the prostate 
(TURP) specimens, including 29 low-risk HNPC samples and 24 CRPC samples, 
that contained adenocarcinoma with adjacent benign prostate tissue. 
 
The MDK expression was found to be highly upregulated in CRPC compared to 
HNPC. The MDK staining was mainly observed in the cytoplasm, but occasionally 
in the nucleus, and included both general staining and areas of a distinct scattered or 
nested cells appearance. The scattered MDK appearance was mainly observed in 
CRPC specimens, and the occurrence and amount of MDK increased with tumor 
aggressiveness (dedifferentiation). Due to the characteristic appearance of the 
scattered MDK staining, it was presumed to belong to NE-like cells, which led us to 
investigate a possible relation between MDK and NED and therefore to analyze the 
NE-marker CHGA and the early neuronal marker TUBB3.  
 
In addition to the expression of MDK in cancer, we could observe the initiation of 
MDK expression in premalignant lesions such as PIN, usually as a general 
cytoplasmic staining but sometimes as a solely MDK-positive NE-like cell. MDK 
could sometimes also be observed in other deregulated glands such as solely MDK-
positive NE-like cells in PIA. Furthermore, in these areas of deregulated glands, 
MDK could occasionally also be observed in infiltrating immune cells such as 
macrophages or in the endothelial cells of blood vessels. Collectively, these results 
demonstrate that MDK is induced early during the initiation and progression of PC. 
 
As observed for MDK, both CHGA and TUBB3 were found to be highly upregulated 
in CRPC compared to HNPC tumors. All three markers, but especially TUBB3, also 
had very low expression in the HNPC specimens. The distinct difference in 
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expression between low-risk HNPC tumors and CRPC tumors links the upregulation 
of all three markers to an advanced and/or CR state. 
 
MDK and TUBB3 were found to have both general and scattered appearances, while 
CHGA was mainly found to have a scattered staining appearance, typical of NE/NE-
like cells. The scattered MDK appearance was confirmed to be expression in NE-like 
tumor cells because CHGA was found to have a similar expression pattern as MDK 
and because MDK-positive NE-like cells were found to co-express CHGA or, more 
commonly, CHGA together with TUBB3. MDK hotspots of sparse scattered staining 
appearance were found in both HNPC and CRPC tumors, while large amounts of 
scattered staining were found exclusively in CPRC specimens. MDK-expressing NE-
like tumor cells therefore increased with the progression of PC and were associated 
with the CR state. 
MDK was furthermore found to be highly expressed in both CHGA and in TUBB3 
hotspots, and expression of MDK in these hotspots was associated with CHGA 
together with TUBB3 as triple expressions or with either marker alone as double 
expressions. CHGA and TUBB3 were rarely found to be co-expressed unless MDK 
was also present. Collectively these results suggest MDK to represent an over-
bridging marker between different populations of NE-like PC cells in CRPC. 
As a generic NE marker, CHGA was expressed in both NE cells from normal glands 
and in NE-like tumor cells in PC, in contrast to both MDK and TUBB3, which were 
only expressed in NE-like tumor cells in cancerous lesions. 
 
In cancer lesions, CHGA was mainly found with a scattered appearance, and this in 
areas of varying levels of differentiation, while TUBB3 was found with both general 
and scattered staining, but an intense general staining for TUBB3 was only seen in 
poorly differentiated areas and thus appears to be strongly associated with 
aggressiveness. Although widely expressed, it should be emphasized that the 
expression of CHGA was also increased along with dedifferentiation in CRPC, but 
not to the same extent as TUBB3.  
 
Furthermore, while MDK expression generally displayed a good accordance with 
TUBB3, including both general and scattered staining, CHGA was primarily 
associated with TUBB3 scattered staining. TUBB3 and CHGA were rarely seen to be 
co-expressed unless MDK was also present. Collectively, these results suggest that 
CHGA and TUBB3 expression can differentiate between tumors, where CHGA is 
expressed in a broader differentiation range, including both HNPC and CRPC 
tumors, while TUBB3 is predominantly expressed almost exclusively in more de-
differentiated CRPC tumors. There is however a large overlap between CHGA and 
TUBB3 expressing cells and MDK expression is seen in both populations. Taken 
together, these results suggest that TUBB3 might be a possible marker for high grade 
(poorly differentiated) NE-transformed cells in PC, similar to the previously 
suggested role for TUBB3 as a marker for pulmonary cancer [46].  
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In conclusion, MDK was found to be significantly upregulated in CRPC tumors and 
was further found to be co-expressed with both CHGA and TUBB3 in CRPC tumors.  
The results of this study suggest that MDK is expressed in overlapping populations 
of NE-like tumor cells with different characteristics and/or differentiation status, 
possibly as part of the NED process. In these transformed tumor cells, MDK might 
also be involved in inducing lineage plasticity and in the acquisition of different 
resistance mechanism or in survival signaling. In addition, MDK was detected as a 
weak/spares staining in premalignant lesions and thus represents an early tumor 
marker in PC. Collectively, MDK represents a promising candidate biomarker in PC. 
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4.2   The role of Midkine in high‐grade prostate cancer cells before and 
after steroid deprivation (PAPER II) 
 
Based on the previous results showing upregulation of MDK in CRPC and its 
association with NED, we sought to evaluate the biological function and impact of 
MDK in PC, both in an androgen-sensitive state and in relation to NED in response 
to castration (in vitro steroid deprivation). For this study, the PC cell line LNCaP was 
used as a model and was cultured with steroids (FBS) – representing the basal state, 
and without steroids (DCC) – representing the steroid-deprived state, this for up to 20 
days. The cells were also administered androgens in the form of DHT. 
 
In Paper II, MDK was confirmed to be expressed in LNCaP cells under basal 
conditions and was shown to play a fundamental biological role at this stage, by 
promoting proliferation and affecting essential gene expression. More specifically, 
MDK silencing by siRNA resulted in the downregulation of a large number of genes 
involved in essential biological processes such as DNA replication and repair, in the 
cell cycle, including the G1/S checkpoint, and telomere maintenance. MDK silencing 
also resulted in a large number of upregulated genes related to processes such as cell 
migration, the inhibition of cell differentiation, and TGF-beta signaling.  
 
Interestingly, many of the biological processes found to be associated with MDK 
silencing in the presence of FBS are processes known also to be associated with AR 
signaling, including DNA replication and repair, telomere maintenance, and 
proliferation (27). Furthermore, many of the signaling pathways and biological 
processes that were affected in the presence of FBS in response to MDK silencing, 
including both upregulated and downregulated genes, are similar to the effects 
observed in response to castration (DCC-treated cells vs. FBS-treated cells) in vitro. 
For example, steroid deprivation of LNCaP cells is associated with the 
downregulation of genes associated with the cell cycle and with, DNA replication 
and repair, as well as with the upregulation of genes associated with adhesion, 
synapse formation, axon guidance, pluripotency signaling, and TGF-beta signaling, 
which was similar to the effect of MDK silencing in FBS-treated cells (results not 
shown).  
 
Collectively, these results suggest a strong relationship between MDK and androgen 
signaling in the steroid-supplemented basal state based on both the number of genes 
affected by MDK silencing and on the many similarities with AR signaling. To 
further support the association between MDK and  AR signaling, several of the genes 
that were upregulated in response to MDK silencing in FBS-treated cells are known 
AR-regulated genes, for example, AGR2, AZGP1, CRYM, EAF2, IGFBP3, and 
LPXN, which is also an AR co-activator associated with PC progression.  
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The profound biological importance of MDK in androgen-sensitive PC presented in 
the paper II suggests that MDK represents a possible target in advanced HNPC, and 
the potential for this needs to be thoroughly evaluated. In support of the importance 
of MDK for PC progression, several of the genes originally suppressed by MDK in 
FBS-treated cells were inversely associated with PC (for example, AZGP1, CRYM, 
EAF2, and IGFBP3), while MDK silencing downregulated several PC-promoting 
genes (for example, OR51E1 and TM4SF1). 
 
In response to steroid deprivation, MDK displayed a profound but transient 
upregulation (with a peak at around 8 days of steroid deprivation), and this was 
associated with the initial phase of castration-induced NED as demonstrated by the 
concomitant upregulation of several NE/neuronal markers as well as an obvious 
morphological NE transformation, including tapering cell bodies and neurite 
protrusions. The initial phase of castration was also associated with the apparent 
upregulation of stem cell/dedifferentiation markers, and this provided supporting 
evidence for simultaneous NE/neuronal transformation and acquisition of stem cell 
features, as recently suggested by others (75, 106, 112). 
Steroid deprivation in combination with DHT administration inhibited most of the 
effects of castration-induced NED, in terms of both marker expression and cell 
morphology, and this supports a repressive role for androgens in NED (92). 
However, in contrast to the other markers that were analyzed, castration-induced 
upregulation of the neuronal marker TUBB3 and the PC stem cell marker CD133 
was not inhibited by DHT supplement, but instead was stimulated. Both TUBB3 and 
CD133 therefore seem to be stimulated by androgens, and thus some repressive 
factor might be present in normal FBS that is not found in DCC. 
 
TUBB3, a tubulin beta isoform and hence a component of microtubules, is 
upregulated in various human carcinomas (177), including CRPC, as observed by us 
(paper I) and by others(178, 179). In CRPC, TUBB3 is associated with poorly 
differentiated tumors and NED (paper I).  
TUBB3 is characterized by enhanced tubulin depolymerization activity, and in 
various human carcinomas TUBB3 expression is associated with poor prognosis and 
with resistance to tubulin-targeting drugs such as docetaxel (a microtubule stabilizing 
drug) (177). Because the study for paper 2 indicated that TUBB3 is induced by DHT, 
the efficiency of docetaxel in CRPC might be improved by combining docetaxel with 
different AR-targeting therapeutic options. In support of this, a combination therapy 
of docetaxel and ADT for patients with metastatic HNPC has recently been shown to 
substantially increase survival times (38, 69, 73).  
 
In contrast to the major impact of MDK in the presence of steroids, during the initial 
phase of castration MDK silencing resulted in limited alterations in gene expression. 
A functional role of MDK at this stage could, however, be demonstrated by an 
MDK-dependent increase in survival. Furthermore, it was demonstrated that MDK 
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depletion downregulated the expression of a subset of genes associated with PC 
progression. Of specific interest was androgen-regulated AGR2, which has been 
associated with metastasis and an aggressive NE subgroup in CRPC (180), which 
suggests an association of MDK with both aggressiveness and the NE phenotype 
during the initial phase of castration. 
 
In comparison to clinical data from our study in paper I, where MDK was 
significantly upregulated in the CR state, the steroid deprived state in paper II 
represent the initial phase of castration with cells still dependent on classical 
androgen signaling and in which MDK expression was clearly affected by the 
androgen status. We therefore hypothesized that the observed upregulation of MDK 
in the early phase of steroid deprivation is an attempt by the cells to maintain the 
many MDK-regulated cellular processes, and maybe also to compensate for the loss 
of AR signaling. However, the obvious similarity between the expression profile of 
MDK and several NE markers during this phase also suggested an association 
between MDK and NED. Furthermore, due to the high expression of MDK in 
CRPC(149, 150), in which the AR signaling axis is normally restored (31), we 
hypothesized that MDK regains, at least partially, the impact on cellular functions 
that it has in the androgen-sensitive state.  
 
A functional role for MDK under both basal conditions and in response to steroid 
deprivation was further supported by the expression of MDK receptors in the LNCaP 
basal state, several of which were also upregulated by steroid deprivation. Potential 
receptors responsible for promoting MDK-dependent survival, as observed during 
castration, include ALK and LRP1, of which LRP1 also displayed castration-induced 
upregulation. PTPξ, another MDK receptor associated with survival, was, however, 
not found to be expressed in LNCaP cells. Potential receptors for the possible 
involvement of MDK in castration-induced neurite outgrowth include members of 
the syndecan family (SDC1, SDC3, and SDC4), GPC2, and NGC, of which, SDC1, 
SDC3, and SDC4 were found to be expressed in LNCaP cells in the study for paper 
II. Furthermore, the involvement of MDK in mechanisms of lineage plasticity and 
EMT and in diverse resistance mechanisms might be derived from Notch2 activity 
under both basal and steroid-deprived conditions in LNCaP cells. Finally, the 
observed MDK-dependent proliferation seen under basal conditions might be derived 
from ALK activation, which in addition to promoting survival is also is involved in 
growth promotion and is expressed in both the basal and the steroid-deprived state. 
The potential involvement of LRP1 and ALK in the MDK-dependent promotion of 
survival and proliferation, respectively, would be interesting to evaluate, for 
example, through the use of receptor inhibitors or neutralizing antibodies under basal 
and steroid-deprived culture conditions.  
 
In conclusion, the study for paper II demonstrated that MDK has a significant impact 
in PC cells in the presence of steroids and that it affects fundamental biological 
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processes, including DNA replication and cell proliferation, probably in close 
association with androgen signaling, and these results might be translatable to 
advanced HNPC. In addition, MDK affects the biology of PC cells during early 
steroid deprivation, thus connecting MDK to the process of castration-related 
progression in terms of aggressiveness and increased survival. Furthermore, we 
hypothesized that when MDK is upregulated in CRPC it regains, at least partially, 
the impact on cellular functions that it has in the androgen-sensitive state together 
with the restoration of AR signaling. In addition, it is possible that truly androgen-
independent mechanisms of MDK signaling might emerge due to the many receptor 
and signaling pathways involved in MDK signaling. 
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4.3  Midkine as a biomarker in advanced prostate cancer (PAPER III) 
There is currently a lack of reliable biomarkers for PC diagnosis, prognosis, and 
treatment prediction as well as for monitoring disease progression (38). One of the 
major challenges within the PC field is the discrimination between indolent and 
aggressive forms of low-risk localized PC, which is why new biomarkers strongly 
associated with aggressiveness and clinical progress are urgently needed. Likewise, 
biomarkers that can predict NED and the development of NEPC are also needed for 
the prediction of treatment outcomes. Based on our previous and parallel findings of 
MDK in PC concerning its expression pattern, responsiveness to steroid deprivation, 
and functional impact, we sought to evaluate the applicability of MDK as a clinical 
progression biomarker in advanced PC before and during ADT.  
 
The prognostic value of MDK was assessed both in plasma and in primary tissue 
both at baseline (pre-ADT) and at the time of relapse into CR growth. This was done 
in relation to established prognostic factors in current clinical use, including clinical 
(TNM staging) and pathological (GS) factors and serum biomarkers (PSA and ALP). 
Furthermore, the NE markers CHGA and NSE were included in the analysis because 
we wanted to evaluate the association of MDK with increased NED as well as to 
assess the prognostic performance of MDK in relation to these NE markers.  
 
In several recent studies on different human carcinomas, circulating MDK has been 
evaluated and proven to be closely associated with cancer progression (131, 151-
155). In this study we showed that plasma MDK is also a powerful progression 
biomarker of advanced PC. More specifically, plasma MDK, both at baseline and 
even more so at relapse, was shown to be a negative prognostic marker for cancer-
specific survival (CSS) and was found to be an independent marker. Furthermore 
MDK outperformed all other prognostic factors commonly used in PC clinical 
settings, especially at relapse. 
Unlike plasma MDK, tissue (primary tumor) MDK was only found to be a weak 
biomarker for CSS at baseline and showed no association with CSS at the time of 
relapse.  
 
The observed discrepancy between plasma and tissue MDK as progression 
biomarkers was supported by their complete lack of correlation, both at baseline and 
at relapse, and this is likely explained by the contribution of MDK from circulating 
tumors cells and from metastatic and pre-metastatic sites, which are accounted for in 
plasma measurements but not in the evaluation of primary tissue. Plasma MDK thus 
represents an estimate of the total tumor burden and also reflects a more progressed 
disease. 
The lack of translation between plasma and tissue MDK seen in this study concerns 
advanced stages of PC (pre-ADT and at relapse), and it is likely that there is some 
translation at an earlier progression time point before metastatic dissemination. 
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In this study, MDK was confirmed to be increased in advanced PC compared to low-
risk localized PC (paper I)(150) and to be affected by castration (paper II). Like PSA, 
MDK displayed a temporary decrease after castration but began to recover around 
the time of relapse. In comparison to PSA and ALP, MDK displayed a robust and 
positive correlation with both markers. Furthermore, MDK displayed a robust and 
positive correlation with pathological grade (GS) and with M-stage (distant 
metastasis), but not with T-stage (tumor). 
Concerning the NE markers CHGA and NSE, plasma MDK showed a positive 
correlation with the plasma levels of both markers at baseline but not at relapse. The 
observed loss of correlation between MDK and NE markers after castration is 
probably, at least partly, explained by the fact that CHGA and NSE, unlike MDK, are 
unaffected by castration. It should also be noted that CHGA and NSE did not have 
any correlation with each other at baseline or at relapse, confirming the 
heterogeneous nature of NE and NE-like tumor cells. 
None of the NE markers had any prognostic value at baseline, while CHGA had a 
weak prognostic value at relapse that was enhanced by NSE, but this prognostic 
value was completely confounded by plasma MDK. This suggests that the power of 
CHGA as a prognostic marker increases with CRPC progression as well as in 
combination with other NE markers as previously suggested (53). Furthermore, these 
results indicate that MDK might identify pre-treatment patients who are predisposed 
to the development of increased NED, and might account for at least some of the 
aggressiveness associated with NEPC, and these hypotheses need to be tested in 
future studies. The results also indicate that MDK, in addition to NEPC, identifies 
aggressive variants of anaplastic CRPC without typical NE features such as CHGA 
and NSE expression, thus offering a more widely applicable biomarker for 
aggressiveness. 
 
In this study, circulating MDK was confirmed as being a powerful negative 
prognostic biomarker, but these results need to be further tested in well-controlled 
prospective studies. However, based on the findings in this work, it is tempting to 
speculate that patients with a high MDK level at baseline might benefit more from 
some alternative primary treatment than from ADT alone, such as upfront 
chemotherapy and radiation. Furthermore, for prognostic evaluation of locally 
advanced and metastatic HNPC, our results suggest that circulating MDK alone or in 
combination with T-stage might be the best prognostic option, while circulating 
MDK alone, being superior, is the best prognostic option for evaluation at relapse 
post-ADT. 
We speculate that MDK could be used together with PSA to screen for aggressive PC 
at an earlier stage than in this study. We also speculate that MDK can aid in the 
identification of patients who are predisposed for NED and the development of 
NEPC and that systemic MDK might therefore assist in the selection of treatment. 
Furthermore, the possibility of using MDK as a therapeutic target should be 
evaluated.  
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4.4  Long‐term steroid deprivation transforms prostate cancer cells to 
anaplastic castration resistant cells (PAPER IV) 
In order to be able to prevent or at least prolong the time until relapse into CRPC, as 
well as to be able to efficiently target CRPC growth, we need to better understand the 
biology behind castration-induced transformation, including the NED process. This 
study therefore aimed to evaluate the process of long-term castration-induced 
transformation, including the NED process and its relation to AR signaling. 
Furthermore, based on previous findings for MDK, including its profound 
upregulation in CRPC (paper I), its association with NED (papers I and II), its 
responsiveness to castration (papers II and III), and its biological impact in PC (paper 
II), as well as its functional association with both survival and proliferation (paper 
II), we sought to evaluate the expression and effect of MDK throughout the process 
of transformation and ultimately in CR growth. 
 
For the evaluation of long-term steroid deprivation in PC, we used the LNCaP cell 
line as a model, which was the same androgen-sensitive PC cell line that was used 
for the short-time steroid deprivation study in paper II. In this study, LNCaP cells 
were subjected to continuous steroid deprivation in two independent experiments – 
LNstarv.1 and LNstarv.2. Furthermore, steroid-deprived cells at different time-points 
after the initiation of steroid deprivation were subjected to the administration of 
DHT, to the reintroduction of FBS-containing media, to the AR-targeting drug 
enzalutamide (for studies of AR inhibition), and to stringent steroid deprivation in 
the form of neural stem cell media, this mainly in the second experiment (LNstarv.2).  
 
In this study, continuous steroid deprivation was observed to sequentially transform 
the androgen-sensitive PC cell line LNCaP into highly proliferative CR cells via a 
stem cell-enriched NE phase and a subsequent colony-forming phase. This 
transformational process was observed in both LNstarv.1 and in LNstarv.2 cells and 
suggested that classical NED only represents a transient and adaptive phase during 
the progression towards CRPC. 
The different morphological phases were overlapping, and the transformations were 
gradual, especially between the NE phase and the colony-forming phase. The 
morphological phenotypes that were associated with the different phases were similar 
but not completely consistent between the LNstarv.1 and LNstarv.2 experiments, and 
LNstarv.1 required a longer time within both the NE and the colony-forming phases 
before transition.  
 
The NE phase was characterized by growth cessation, a typical NE morphological 
switch (tapering cell bodies and neurite protrusions), and the upregulation of diverse 
NE and neuronal markers such as NSE, MAP2, and NCAM1 (CD56).  
The observed NE phase was furthermore associated with dedifferentiation and 
stemness based on the observed upregulation of induced pluripotency markers such 
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as POU5F1, SOX2, and NANOG. The NE-like tumor cells also displayed an 
overlapping EMT with the upregulations of, for example, SNAIL and VIM, and the 
NE-like tumor cells also displayed a modest AR downregulation in association with 
ceased expression of AR target genes such as PSA, TMPRSS2, and NXK3.1. Finally, 
confirming our earlier study (paper II), MDK was observed to be transiently 
upregulated in the NE phase and to have a similar expression pattern as many 
NE/neuronal markers and dedifferentiation markers. The association of NED with 
both dedifferentiation and EMT was more pronounced in LNstarv.1 compared to 
LNstarv.2 cells, where LNstarv.1 represented the first experiment and cells that were 
subjected to a presumably more stringent castration treatment due to the efficiency of 
DCC complementation. A comparison between the two DCC products is planned for 
the future. 
 
The subsequent colony-forming phase was characterized by small cells that were 
tightly packed, with or without neurite protrusions at the colony borders and showing 
gradually increasing proliferation. The colony-forming cells were further 
characterized by a reduction in NE/neuronal markers and a reduction in induced 
pluripotency markers, but they showed sustained expression of EMT markers and 
increased expression of PC stem cell markers (upregulation of CD133 and recovery 
of CD44) and the neural stemness-associated transcription factor HES1. Furthermore 
there was altered expression of genes involved in reprogramming (upregulation of 
XIST and downregulation of REST), which could indicate overall epigenetic 
instability and transformational reprogramming. 
The colony-forming phase thereafter gradually transformed into a scattered cell type 
with a small cell morphology (high nucleus to cytoplasm ratio, round to oval shape) 
in combination with a continued increase in proliferation. The colony-forming phase 
represents a relatively short transition phase between the adapting phase of NED and 
the CR state of growth-modified and proliferative CR progeny.  
 
In addition to the morphological switch at the recovery in proliferation described 
above, the CR terminal state was characterized by an upregulation of the AR. In 
association with AR upregulation, there was a massive alteration in gene expression.  
Several NE/neuronal and pluripotency markers were recovered from the NE phase, 
for example, NSE, AMACR, NR5A2, NANOG, and KLF4, while others mainly had a 
peak and pronounced upregulation during the CR state, for example, the stemness 
marker GABRB3, the primitive neuronal markers NES (nestin) and EOMES, and the 
early neuronal marker TUBB3. Furthermore, markers associated with EMT were 
found to have continued upregulation, for example VIM, SNAIL, and BMP4.  
These data are in line with recent studies and suggest an association between NED 
and stem cell-like phenomena, i.e. the acquisition of stemness by NE-like tumor cells 
during the progression of PC (18, 24, 26), a causal relationship that could explain 
many aggressive features in CRPC. The results also suggest that AR recovery is 
associated with dedifferentiation in CRPC. 
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Furthermore, MDK, which was downregulated in the colony-forming phase, was 
recovered and upregulated at CR transition, and this was associated with the 
upregulation of many of its receptors (including LRP1, SDC3, and NOTCH2) as well 
as with upregulation of TUBB3. These results confirm our earlier theories of regained 
MDK expression and activity in the CR state of PC. Furthermore, these results also 
support theories of androgen regulation of both MDK and TUBB3 expression in PC.  
In addition to the upregulation of genes associated with dedifferentiation, neuronal 
characteristics, and EMT, there was upregulation of genes associated with general 
aggressiveness and cancer progression, for example, SHH, CD24, and CTNNB1 and 
the transcription factors JUN, FOS, and LEF-1. 
 
The AR was confirmed to have a nuclear localization and to be growth promoting in 
the CR state, but without any recovery in AR-regulated genes such as PSA and 
TMPRSS2, suggesting an altered signaling axis in these cells.  
In addition to the observed AR upregulation, altered steroidogenesis (upregulation of 
AKR1C3 and SRD5A1) and/or potential bypass mechanisms (upregulation of steroid 
hormone receptors ESR1 and PGR) were indicated to be involved in the acquired AR 
activity. Furthermore, the AR might be activated through crosstalk mechanisms, for 
example, by the neuropeptide NT (neurotensin), which is known for this activity (83) 
and to have a high mitogenic activity in an androgen deprived condition (83, 98, 
100), in addition to its observed pronounced upregulation in the CR state. The 
mechanism of AR activation in the CR state should be further evaluated, including an 
analysis of ARVs, of which ARV7 is of greatest interest. 
In this study, in addition to the confirmed nuclear localization, the AR was confirmed 
to be growth promoting, even after prolonged steroid deprivation, and was shown to 
be essential for proliferation and survival and likely also for the differentiation status.  
 
Inhibition of AR signaling by the administration of enzalutamide resulted in a 
pronounced effect on morphology, survival, and proliferation in steroid-deprived 
LNstarv cells. Inhibition of growth and survival by enzalutamide was, however, more 
pronounced and of longer duration in the colony-forming phase compared to the CR 
state, in which rapid recovery was observed. Resistance mechanisms in the colony-
forming phase further involved short-lived NE features, supporting NED as a 
resistance mechanism as well as suggesting that NED is inducible multiple times 
during acquired resistance. In contrast, the morphological impact of enzalutamide 
observed in the colony-forming phase in cells of the CR state was relatively short-
lived and mild, and the associated alteration needs to be further evaluated at the 
mRNA and protein level. Collectively, the results suggest that AR-targeting drugs 
such as enzalutamide might be efficient on the reactivated AR in CRPC, although 
therapeutic efficacy might not be detected by effects on PSA levels. However, AR-
targeting drugs is likely more efficient before transformation to a fully CR state has 
been achieved. 
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The capacity of LNstarv cells, both from the colony-forming phase and the CR state, 
to survive and proliferate in neural stem cell media, i.e. during stringent castration, 
was confirmed to be enhanced and completely AR dependent. Spontaneous spheroid 
formation and dedifferentiation to a presumed primitive state was induced in cells 
from both the colony-forming phase and the CR state. AR targeting resulted in the 
inhibition of spheroid formation, ceased proliferation, and massive cell death, and 
there was no recovery with time. Collectively, these results suggest that the AR 
might be efficiently targetable in the CR state if a state of complete castration is 
achieved.  
 
Reintroduction of androgen to the steroid-deprived cells demonstrated the 
reversibility of the transformation process to encounter more resistance with 
prolonged starvation time and with the progression state of the cells. In the NE phase 
and early colony-forming phase, which are associated with the expression of NE 
markers and stem cell markers, the reversion was relatively rapid and complete, 
while in the fully CR state the cells did not respond to steroids with reversion but 
instead with increased proliferation. Furthermore, androgens in the form of DHT had 
a toxic effect in the early colony-forming phase, and slightly so also in the late 
colony-forming phase, indicating that the cells were sensitized to DHT or that they 
did not use this androgen for activation at this stage. 
These results identify different effects of androgens during the progression into 
CRPC, and these might be important to consider in relation to the reintroduction of 
steroids in the clinic. 
 
Major findings in this study include the observed gradual process of castration-
induced transformation and the sequential transformation of LNCaP cells into a 
terminal CR state via a phase of classical NED and a subsequent colony-forming 
phase. Furthermore, we made the observation that MDK was associated with both the 
NE phase and with CR growth, that MDK was recovered in association with the AR, 
and that the AR was confirmed to be growth promoting and associated with 
proliferation, survival, and differentiation status in the CR cells. 
From this and previous studies, we hypothesizethat MDK has a functional role both 
during NED induction and in CR growth and that MDK and the AR are functionally 
associated. Furthermore we propose that classical NED represents a transient phase 
that is closely associated with dedifferentiation and is inducible multiple times as a 
mechanism of adaptation and associated transformation.  
 
Interpretations of the results from this study must be made with caution, however, 
because they were obtained from only one cell line, and they need to be confirmed in 
other studies as well as in other PC cell lines, for example, in VCaP and/or LAPC4 
cells. In addition, LNCaP cells, which were used as the PC model in this study, carry 
a T877A mutation in the ligand binding domain of the AR, making it, in addition to 
androgens, also responsive to progesterone and estrogen (52), and this might have 
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influenced the final results. Furthermore, the expression data presented in this paper 
need to be verified at the protein level as well as through regular Q-PCR, which is an 
ongoing project. 
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5 GENERAL DISCUSSION 
Metastasized HNPC and CRPC both represent incurable stages of PC pathogenesis 
despite several therapeutic advances in recent years. Treatment advantages for 
patients with metastasized HNPC involve combination treatments on a backbone of 
ADT, and ADT in combination with the cytotoxic drug docetaxel has resulted in a 
substantial survival benefit in comparison to the administration of ADT alone (38, 
69, 72, 74). However although an increased survival rate is obtained, most patients 
ultimately relapse into lethal castration resistant prostate cancer (CRPC) as therapy 
fail. 
5.1 LETHAL PC 
CRPC is lethal and normally results in cancer-related death within 3–4 years due to 
complications associated with metastatic disease (69). Despite recent advances also 
at this stage, including the use of the potent AR/androgen-targeting drugs 
enzalutamide (targets the AR) and abiraterone acetate (targets androgen 
biosynthesis), the treatment is only palliative and the response durations are 
relatively short due to different mechanisms of acquired resistance. Eventually, 
highly resistant variants of PC emerge that no longer respond to any available 
treatment (69, 74, 75, 97, 122). 
In addition to the lack of curative treatments for patients with metastasized HNPC 
and CRPC, there is an urgent need for reliable biomarkers for disease monitoring and 
prognostics. 
 
PSA represents the primary biomarker in PC but has limitations concerning both 
sensitivity and specificity, and thus it cannot discriminate between indolent and 
aggressive forms of low-risk PC and is insufficient in disease and therapy 
monitoring, especially in late stages of the disease (38). We therefore need new 
biomarkers to use in addition to or alongside PSA to be able to make better 
diagnostic and treatment decisions. 
 
To be able to develop curative treatments, or at least long-lasting palliative 
treatments, for patients with advanced HNPC and CRPC, we need to better 
understand the process of castration-induced transformation in terms of acquired 
resistance, including AR-related mechanisms, stem cell-related dedifferentiation, and 
NED. We also need to find targetable drivers responsible for these transformations 
that can be used in combination with or instead of AR targeting. 
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5.2 CRPC  TRANSFORMATION  
PC is generally an AR-driven disease, and current therapies therefore largely focus 
on androgen ablation and AR-targeting therapies. Resistance mechanisms to these 
therapies largely involve AR-related mechanisms that sensitize and restore AR 
activity and/or signaling (31). Before transformation into a CR state, the tumor 
undergoes massive cell apoptosis. The surviving cells comprise those cells that can 
survival despite castrate levels of testosterone, including cells already androgen 
independent (e.g. prostate stem cells and NE cells) and/or androgen-dependent cells 
that are capable of a rapid adaption (21, 24, 181), such as the commitment to NED, 
which is the transdifferentiation process of NE-like tumor cells from luminal 
epithelial cancer cells (21). These NE-like tumor cells are characterized by androgen 
independence, ceased proliferation, and high resistance to apoptosis as well as by a 
general dedifferentiation, including the upregulation of pluripotency markers (21, 52, 
86) as demonstrated in the present thesis (papers II and IV). The NE-like state is 
furthermore both reversible (182) and temporary, representing a transition phase as 
seen in paper IV. This window of dedifferentiation and transformational 
reprogramming, before the emergence of CR disease, might be efficiently targetable 
if focusing on the right driver. The AR is possibly also targetable at this stage, as 
seen in paper IV where the growth and survival of colony-forming steroid-deprived 
cells was temporarily inhibited by enzalutamide. However, targeting the AR at this 
stage is likely not enough. Possibly, however, targeting a driver associated with a 
primitive state or with associated reprogramming, for example, EZH2, might be more 
efficient. It is likely, however, that a combination therapy targeting several drivers 
will be needed.  
 Targets in NED and in CRPC 5.2.1
In recent years many candidate drivers for NED and the development of NEPC have 
been suggested, for example, AURKA and MYCN; however, none so far have been 
proven to be associated with a clinical survival benefit (113, 115, 122). Interestingly, 
in paper IV, AURKA was downregulated during the early stages of steroid 
deprivation-induced transformation (in the NE phase and the colony-forming phase), 
and its expression was recovered at the transition to the CR state in association with 
the upregulation of AR. These results might support the upregulation of AURKA in 
NEPC, but they contradict AURKA as a driver of NED. A driver for NED and 
presumably also for NEPC should optimally represent an early marker or event 
during the transformation process and thus be strongly associated with the initiating 
phase of NED.  
REST is another gene with a reported strong association with NED (108) that is 
downregulated during NED, but in paper IV it was shown to be upregulated in 
association with CR transition and AR recovery. REST has been reported to have a 
strong association with the AR (108), and in addition to its known repressive 
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functions in neuronal differentiation it has recently been assigned a tumor-promoting 
role in neural cells and shown to be involved in EMT and in stem cell self-renewal 
(106). Furthermore, REST is highly expressed in stem cells, including neuronal 
progenitors (107). Collectively, the upregulation of REST in LNstarv.1 cells supports 
an active AR in these cells as well as a primitive neuronal state, because several 
primitive neuronal markers, including NANOG, EOMES, TUBB3, and NES (nestin), 
were upregulated in parallel with REST and AR. 
Finally, an efficient target for NED, as part of the transformation process, might be 
targetable within the transformation window for PC in general regardless of a 
predisposition for NEPC or not. 
 The AR in CRPC 5.2.2
In the CRPC, at least in therapy-naïve CRPC, the AR generally represents the main 
driver for disease initiation and progression; however, it is difficult to efficiently 
target due to mechanisms of acquired resistance (31). The AR might, however, be 
more efficiently targetable if a completely castrated context could be achieved, as 
seen in paper IV concerning the devastating effect of enzalutamide administration 
during stringent steroid deprivation. In vivo, however, such a stringent castration is 
hard to achieve due to the presence of background adrenal androgens and acquired 
intratumoral steroidogenesis. 
An absolutely essential role of the AR in CR growth after prolonged steroid 
deprivation was therefore observed in paper IV, and this involved survival, 
proliferation, and differentiation status. These results were obtained in LNstrav.2 
cells and should be verified in LNstrav.1 cells. The CR state in LNstrav.1 cells was 
however associated with marked AR upregulation, which was in association with 
massive gene alterations, but without any PSA expression, which might be indicative 
of an altered androgen/AR signaling axis. The characterization of LNstrav.1 and 
LNstarv.2 is an ongoing project and might reveal the acquisition of different 
resistance mechanisms in these sublines. 
 NED as a transient phase of adaptation 5.2.3
In paper IV, continuous steroid deprivation was observed to sequentially transform 
LNCaP cells into a highly proliferative CR state, and classical NED was shown to 
represent a stem cell-enriched phase during this progression. The NE phase later 
merged into a colony-forming phase that gradually transformed further into the CR 
progeny. NED was also observed as a transient adaptive response in colony-forming 
cells in response to enzalutamide (paper IV). NED has also been reported clinically 
to be part of the acquired resistance in CRPC (31, 76, 77). 
Additionally, before reaching the fully transformed state of CR growth, the process 
of castration-induced transformation was shown to be reversible by the re-
introduction of androgens. In the terminal CR state, however, the transformation 
process was not reversible but the androgens were instead shown to be growth 
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promoting. Collectively, these results suggest that NED represents a transient 
adaptive phase that is associated with dedifferentiation and reprogramming and is 
part of a mechanism of acquired resistance. Thus NED in CRPC might be targetable 
with the same procedure as primary NED during CRPC transition if an efficient 
target can be identified. 
5.3 MDK IN PC 
 MDK expression in PC  5.3.1
In paper II, MDK was shown to promote proliferation and to alter gene expression 
associated with essential biological processes in androgen-sensitive LNCaP cells 
under basal conditions, and it was suggested that there is a close association between 
MDK and AR signaling and/or AR-regulated genes. The close relationship between 
MDK and AR was further confirmed in paper IV, where a concomitant recovery of 
expression and upregulation of MDK and AR was observed at the transition to CR 
growth. The responsiveness of MDK to steroid deprivation observed in vitro (papers 
II and IV) was further verified clinically (paper III), where MDK showed a similar, 
but not as pronounced, expression profile as PSA. 
 
In paper I, MDK was shown to be upregulated in CRPC tumors and to be associated 
with NED in these tumors. MDK upregulation in CRPC was confirmed in paper III 
where MDK expression started to increase in association with CRPC relapse and to 
continue to increase with disease progression. An association of MDK with NED 
was also seen in vitro, where MDK displayed transient upregulation in response to 
the initial phase of steroid deprivation-induced NED and associated dedifferentiation 
(papers II and IV). MDK was thereafter downregulated during the succeeding 
colony-forming phase but recovered its expression at CR relapse (paper IV). 
Furthermore, MDK had an impact on early steroid deprivation, as shown by MDK-
dependent survival as well as transcriptional association with the pro-metastatic 
AGR2, which is known to be associated with an aggressive NE phenotype in CPRC 
as well as to represent a new promising biomarker for characterization, monitoring, 
and directing therapies for patients with metastatic NEPC (122, 180). 
Collectively these results suggest that MDK and AR are in a close functional 
relationship and that MDK is associated with the NE phase and with CR growth.  
 MDK as a prognostic biomarker  5.3.2
The clinical findings of MDK in paper I suggested a prognostic value for MDK, and 
this was later confirmed in paper III in which circulating MDK was demonstrated to 
be a significant negative prognostic biomarker for CSS in advanced HNPC, pre-
ADT, and at relapse into CRPC. 
 
Anna Nordin 
61 
Circulating MDK furthermore outperformed all other analyzed factors, including 
clinicopathological factors (TNM staging and GS) and biomarkers (PSA, ALP, NSE, 
and CHGA) that are currently in clinical use. In the same study, however, tissue 
MDK levels evaluated from primary tumors were of no prognostic value and were 
therefore not translational to MDK levels measured in plasma. This discrepancy is 
most likely due to the contribution of MDK from pre-metastatic and metastatic sites 
accounted for in plasma levels but not to the levels in primary tumors. 
A high MDK level is thus associated with a short survival time both in advanced 
HNPC and at transition to CRPC. Circulating MDK might therefore represent a 
marker for aggressiveness and as such be able to differentiate between slow and fast-
progressing tumors at an earlier stage in disease progression, for example, in 
localized PC. MDK levels in plasma might, however, also be a reflection of total 
tumor burden. To further evaluate the applicability of MDK as a biomarker, it would 
be of specific interest to evaluate the prognostic value of MDK in patients with low-
risk localized tumors with an uncertain clinical progression course, for example, GS 
7 tumors. MDK could potentially differentiate between indolent and aggressive 
variants from an even earlier time point, which should be evaluated separately. 
It should be noted that the CRPC tumors analyzed in paper I (TURP specimens) 
represent advanced CRPC and tumors with a local relapse post-ADT, while the 
tumors analyzed in paper III (patient cohort 2) were prostatic biopsies taken from 
patients at the time of CRPC diagnosis as defined by distant tumor relapse or 
increasing PSA levels, and this is important when considering the non-prognostic 
value of MDK in tumor biopsies in paper III. 
5.4 FUTURE PERSPECTIVES  
 MDK as a predictive biomarker 5.4.1
Due to great variations in patient response duration for different treatments, reliable 
biomarkers for treatment predictions are highly valuable. 
The findings of MDK as a significant negative prognostic biomarker in advanced 
HNPC, both for progression-free survival (results not shown) and for CSS (paper 
III), indicate that patients with a high MDK level will not respond as well to standard 
therapy with ADT as those with lower MDK levels. Instead, they might benefit more 
from some alternative therapy, for example, chemotherapy, but this needs to be 
evaluated separately. Likewise, patients with a high degree of focal NED generally 
respond more poorly to ADT (24, 87, 97), while patients with SCPC (an aggressive 
form of NEPC) are considered unresponsive to ADT and AR-modulating therapies. 
An association between MDK and NED was observed in all papers in this thesis 
work, as indicated by the observed correlation between MDK and the NE markers 
CHGA and NSE in advanced HNPC (paper III), the co-expression of MDK with both 
CHGA and TUBB3 in CRPC tumors (paper I), and the observed upregulation of 
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MDK during the initial phase of NED in vitro (papers I and IV). Furthermore, MDK 
was observed to be upregulated in association with primitive neuronal markers at the 
transition to CR growth (paper IV). 
Collectively, these results suggest that MDK might offer a therapeutic predictive 
value in HNPC, for the evaluation of which, the MDK pre-treatment level should be 
analyzed along different treatment arms and in relation to disease progression. 
 
Due to the strong association of MDK levels at relapse with time to death, the 
predictive value of MDK should also be evaluated at this time point in the treatment-
naïve CR state. For this, the MDK levels at relapse into CRPC should be analyzed 
along different treatment arms and in relation to acquired resistance and survival.  
An evaluation of the predictive value of MDK in relation to therapy with platinum-
based cytotoxic drugs, e.g. cisplatin (interferes with DNA repair), would be of 
specific interest due to its association with NED and NEPC (a patient group that 
might receive this therapy) (53, 122) as well as due to the reported impact of MDK 
on therapy efficiency to this category of drugs (154, 156-158, 160, 161). 
The possible impact of MDK on platinum-based chemotherapy in PC should be 
evaluated separately; however, published data in other cancer forms imply that MDK 
has high value as a therapeutic predictor at least regarding cisplatin, and might 
represents a possible target in combination with cisplatin therapy for certain patient 
groups. 
 MDK as a therapeutic target 5.4.2
Due to the pronounced biological impact assessed in vitro for MDK under basal 
condition (paper II) as well as the observed strong association of MDK with CSS in 
patients pre-ADT (paper III), it might be hypothesized that MDK is targetable in 
patients with advanced HNPC, perhaps in combination with AR targeting.  
The data from this thesis imply that MDK in CRPC might regain its biological 
impact and many of its functions from the basal state (paper II) in association with 
AR re-activation and the restoration of an androgen-influenced context. Furthermore, 
because MDK was identified as an excellent negative biomarker at relapse (paper III) 
as well as being confirmed to be upregulated in CPRC, both in vitro (paper IV) and 
in clinical samples (paper I and III), it is possible that MDK is targetable at this stage 
as well. In CRPC, it would be of great interest to target MDK in a small clinical trial 
composed of patients with multi-resistant and highly aggressive PC variants that no 
longer respond to any available therapies. 
Furthermore, as mentioned earlier, MDK might also represent a target in 
combination with cisplatin therapy as well as a possible target during NED induction. 
 Concluding remarks  5.4.3
Treatment of patients with metastatic PC is rapidly changing with the introduction of 
new drugs, as well as the earlier introduction of both cytotoxic drugs and the new 
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generation of hormonal agents. In this changing landscape, good biomarkers are 
necessary and, MDK represents a cancer biomarker that is of great potential in 
several stages of the disease.  
 
The results from paper III demonstrate MDK to be a powerful prognostic biomarker 
in PC, both in the advanced HNPC stage and at relapse. However, these results need 
to be further verified in well-controlled prospective studies. Furthermore a prognostic 
value of MDK should be evaluated retrospectively in localized PC, especially in 
those with an uncertain clinical progress/risk. MDK as a therapeutic predictor should 
also be evaluated both in HNPC and in therapy-naive CRPC, including if possible 
cisplatin patients. 
 
MDK as a future therapeutic target in both HNPC and in CRPC should also be 
evaluated, primarily by a thorough analysis in preclinical settings. There is a 
humanized neutralizing MDK antibody available (CAB102, Cellmid Ltd.), which in 
a variety of xenograft models been associated with the inhibition of tumor growth 
and metastasis and of angiogenesis and to reduce chemoresistance 
(http://www.cellmid.com.au/content_common/pg-lyramid.seo). In future studies, a 
combined MDK and AR targeting should also be evaluated, based on their mutual 
dependency suggested by the work in this thesis. In addition, several interesting 
genes associated with MDK and NED should be evaluated further as prognostic tools 
and possible drug targets, for example AGR2 identified in the present study.  
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6 CONCLUSIONS 
Based on the results of the present thesis, the following conclusions could be 
made: 
 
 MDK is upregulated along with disease progression in HNPC and 
after relapse in CRPC, resulting in high expression in progressed 
CRPC 
 
 MDK is associated with dedifferentiation and NED in CRPC. 
    
 
 
 MDK appears to be involved in fundamental biological processes in 
androgen-sensitive PC. 
 
 MDK and the AR seem to be functionally connected. 
 
 MDK is associated with increased survival during early steroid 
deprivation, thereby influencing the effect of castration. 
 
 
 
 MDK represents a potentially powerful negative prognostic 
biomarker, in terms of CSS, for both advanced HNPC and at CRPC 
relapse. 
 
 
 
 Steroid deprivation-induced transformation into a CR state is a 
gradual process where classical NED represents a transient phase 
associated with stemness. 
 
 NED is also associated with an adaptive state preceding acquired 
resistance in the CR state. 
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